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Abstract 
The population of individuals with diabetes is expected to rise along with a rise in the 
use of insulin therapy to control hyperglycemia and prevent diabetic complications. 
Insulin therapy is implicated as one of the leading causes of hypoglycemia, a potentially 
life-threatening adverse drug event. Hypoglycemia is recognized by patients and 
clinicians as the greatest barrier to achieving adequate glycemic control and it causes 
physical, psychosocial, financial, and safety concerns for individuals, their families, 
communities and health care systems. Hypoglycemia often causes insulin requiring 
diabetics to develop a fear of hypoglycemia, a complex phenomenon that manifests as 
avoidance of hypoglycemia or near normal euglycemia thus triggering hyperglycemia and 
increasing risk. The fear and risk of hypoglycemia requires attention by clinicians in 
order to assist patients in self-management. The purpose of this evidence based project 
was to add to clinical knowledge and demonstrate how the application of best practice 
strategies can be translated into real world clinical practice to improve quality and 
safety.  All insulin requiring adults evaluated by the advanced practice nurse were 
provided education in accordance to best practice standards. Sixty participants were 
queried pre-intervention and post-intervention with the FH-15 Survey and a 
hypoglycemia incidence survey. The data was comparatively analyzed. Outcomes 
demonstrated that self-management education effectively reduced fear of hypoglycemia 
and incidence of hypoglycemia; however, the intervention was statistically significant in 
reducing fear of hypoglycemia only. Additional scholarly inquiry regarding the topic is 
recommended.  
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Chapter 1: Introduction and Overview 
Hypoglycemia is a potentially life-altering adverse drug event (ADE) and the 
most frequently experienced complication associated with insulin use. This event strikes 
fear in the hearts of insulin requiring diabetics and serves as a major barrier to attaining 
near normal glycemic control (Amiel, 2009). Hypoglycemia is an obstacle for both 
individuals and healthcare providers (HCPs) alike and deters patients from obtaining 
the degree of glycemic control needed for the prevention of long term diabetic 
microvascular and macrovascular complications. The effects of hypoglycemia on the 
individual range from minimally disruptive to life threatening and can have 
accompanying physical, psychosocial, safety, and financial implications. Hypoglycemic 
poses a serious threat to the health and well-being of the diabetic insulin user. The reach 
of hypoglycemia’s effects stretch beyond the individual to influence families, 
communities, and the healthcare system at large.  
Numerous priorities in diabetes care have been identified that continue to require 
translational research including the development of programs in different clinical 
settings, the identification of barriers to management, the discovery of facilitators of 
effective translation, and the shift in the paradigm from an acute care perspective to that 
of a multifaceted chronic care model. It is of the utmost importance that clinicians and 
researchers utilize a population based and patient centered approach to diabetes care 
management and apply best practice standards to revolutionize interventions for 
individuals, organizations, and communities. Interventions must be evaluated for cost 
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effectiveness. Additional translational research investigating the impact of interventions 
on vulnerable populations is imperative to assist with the ethical allocation of valuable 
resources. Translational research in diabetes care also assists in guiding efforts that 
influence public health initiatives and healthcare policy decision making (Garfield et al., 
2003). Regrettably, although tremendous advances have been made over recent decades 
in the field of diabetes research, there is evidence that the application of standards of care 
for the procurement of achieving optimal results in real-world diabetes management 
often falls short. These real world barriers must be tackled by using methods in 
translational research as the attempt is made to move from bench to bedside. 
 It is widely stated that the ability for an insulin requiring diabetic to completely 
eliminate iatrogenic hypoglycemia and maintain near normal blood glucose levels 
consistently over a lifetime cannot be safely accomplished with the treatment methods 
that are currently available. Therefore, until such a time exists, clinicians and patients 
must address the issue of hypoglycemia with what is currently known (Cryer, 2008). 
Hypoglycemia risk factor reduction must first include acknowledgement of the problem. 
The need to address the issue through autonomy supported education, patient 
empowerment, shared decision making and individualized goals is the impetus for this 
evidence based project (EBP). The EBP is intended to add to the knowledge base of 
translational diabetes research and demonstrate how the application of best practice 
strategies can be translated into real world clinical practice in an effort to improve 
quality of care and patient safety.   
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Background 
 Diabetes Mellitus (DM) is a complex and multifactorial metabolic disease 
hallmarked by an absolute or relative insulin deficiency and/or the inability of the body 
to utilize insulin effectively thus resulting in elevations of glucose in the bloodstream. 
According to the American Diabetes Association ADA (2014), it is estimated that 
approximately 18 million people in the United States have been diagnosed with DM and 
an additional 7 million people remain undiagnosed. A more startling statistic is that 79 
million people are estimated to have blood glucose levels that are considered to be 
indicative of pre-diabetes or at risk for DM. This translates to over 100 million Americans 
potentially at risk for developing complications associated with DM. Most cases of DM 
can loosely be categorized into Type 1 DM and Type 2 DM. The distinction between the 
types is generally contingent upon the amount of endogenously produced insulin, the 
hormone secreted by the beta cells of the pancreas responsible for deposition of nutrients 
to the cell through the transport of glucose from the bloodstream to the cells. The 
deficiency of insulin production in Type 1 DM is essentially considered to be absolute 
despite recent studies that indicate that Type 1 diabetics may have some micro-secretion 
of insulin. The deficiency in Type 2 DM is considered to be relative and accompanied by 
a myriad of other physiologic metabolic factors. DM of either type is considered to be a 
disease with the progressive loss of insulin production due to beta cell failure over an 
individualized period of time. Oral medications may provide benefit; however, in Type 1 
DM, as well as advanced Type 2 DM, exogenous insulin becomes a modality that is life-
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sustaining in order to negate the absence of endogenous insulin production and control 
hyperglycemia.  
It is essential to realize the importance of the need for insulin therapy in the 
treatment of diabetes. Chronic hyperglycemia associated with a diagnosis of DM can 
lead to the development of crippling complications. Microvascular complications, such 
as retinopathy, neuropathy and nephropathy, and macrovascular complications, such as 
cardiovascular disease, are prevented by the near normalization of blood glucose levels. 
The near normalization of blood glucose levels frequently requires the utilization of 
insulin therapy in the majority of Type 1 and advanced Type 2 diabetics. Thus, insulin is 
thus considered a life sustaining and life preserving necessity.  
The Centers for Disease Control and Prevention CDC (2013) estimated that 
approximately 2.2 million diabetics utilize insulin therapy alone as a treatment modality 
while approximately 1.7 million additional diabetics use insulin with oral diabetes 
agents. An estimated 12% of the diabetic population use insulin therapy to control their 
DM (United States Department of Health and Human Services HHS, 2014).  This 
defined population represents the number of individuals with DM on insulin in the 
United States who are at risk for the ADE of iatrogenic hypoglycemia. The threat of 
ADEs has prompted government regulatory agencies, such HHS (2014) to develop 
national action planning for the prevention of ADEs. According to this agency, ADEs are 
defined as injuries resulting from drug related medication interventions in any setting. 
ADEs provide the potential for harm and threaten patient safety. It is estimated that 
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ADEs account for an estimated one in three hospital adverse events, 3.5 million 
additional HCP office visits, one million additional emergency department (ED) visits, 
and approximately 825,000 hospital admissions. The three most common pharmacologic 
agents associated with ADEs prompting national action planning include opioids, 
anticoagulants, and diabetes agents, specifically sulfonylureas and insulin.  
Hypoglycemia is the most common ADE associated with insulin use (HHS, 2014).    
Description of the Phenomena of Hypoglycemia.  Hypoglycemia is a major 
limiting factor in the management of DM (Wild et al., 2007). The definition of 
hypoglycemia has been inconsistently cited in the literature. The most recent consensus 
definition of hypoglycemia is a blood glucose (BG) < 70 milligrams/deciliter (ADA, 2014) 
with severe hypoglycemia defined as a hypoglycemic event requiring the assistance of 
another. Hypoglycemia, as previously stated, is said to have physical, psychosocial, and 
financial implications for individuals, families, communities, and the healthcare system. 
Further exploration of the phenomena of hypoglycemia is relevant to this EBP.  
Significance 
 Physical implications.  Hypoglycemia results from a relative or absolute insulin 
excess and progressively compromises the body’s defenses against falling blood glucose 
levels. (Cryer, 2009). The normal physiologic defense by the body during hypoglycemia is 
reduced pancreatic beta cell insulin release, increased hepatic and renal glucose 
production, increased pancreatic alpha cell glucagon release, and cessation of glucose 
utilization by non-neural tissues. These defenses are compromised in the setting of DM.  
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Symptoms of hypoglycemia can be categorized as neuroglycopenic, those 
resulting in brain glucose deprivation, or autonomic, those resulting from stimulation of 
the sympathetic nervous system. Neuroglycopenic symptoms manifest as: cognitive 
impairment, behavioral changes, psychomotor abnormalities, seizures and coma. 
Autonomic symptoms manifest as: palpitations, tremors, anxiety, diaphoresis, hunger, 
parathesias, and pallor.  
A disturbing phenomenon associated with repeated hypoglycemia is the loss of 
counter-regulatory responses to hypoglycemia resulting in the delayed detection of 
symptoms or the absence of symptoms in the individual. Although the previously stated 
definition of hypoglycemia is <70mg. /dl, the threshold for detecting hypoglycemia is 
individualized dependent upon precedent exposure(s) to hypoglycemia and 
hyperglycemia. Ergo, hypoglycemia may also be categorized as any abnormally low 
glucose concentration that exposes the individual to harm (Cryer, 2008).  This concept is 
analogous with a defective thermostat’s inability to detect variations in the room 
temperatures to signal a change in the heating or cooling system as a response. The 
inability of an insulin requiring diabetic to detect hypoglycemia before the overt 
cessation of glucose to the brain occurs poses exceptionally high risks to the individual 
and to surrounding individuals. This form of autonomic dysfunction is classified as 
hypoglycemia unawareness and, despite this particular complication being beyond the 
depth and breadth of this EBP, this EBP has the ability to assist in the prevention of the 
development of hypoglycemia unawareness.  Additionally, hypoglycemia is associated 
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with an increased risk of cardiovascular (CV) events and all-cause mortality in insulin 
treated diabetics. There is a relationship that exists between hypoglycemia and CV 
outcomes and mortality over a long period of time (Khunti et al., 2015). Hypoglycemia is 
noted to prolong QT intervals, increase catecholamine release, and promote 
inflammation and endothelial dysfunction. Although CV disease from chronic 
hyperglycemia remains the primary cause of death in insulin requiring diabetics, the role 
of hypoglycemia cannot be discounted (Khunti et al., 2015).  
The statistics regarding the phenomenon of hypoglycemia demonstrate the 
magnitude of the problem. IoH increases with the duration of diabetes. There is also a 
higher risk of hypoglycemia with autonomic dysfunction, renal impairment, advanced 
age, cognitive impairment, hepatic disease, and psychosocial factors, including fear of 
hypoglycemia (FoH) (Robertson, 2012). The frequency of hypoglycemia is such that it is 
considered a fact of life for most insulin requiring diabetics with the average insulin user 
suffering one to two episodes of disrupting hypoglycemia per week and one or more 
severe events per year (Cryer, 2008). The IoH among Type 2 diabetics, who have 
previously been viewed as having less risk of hypoglycemia in comparison to Type 1 
diabetics, rivals that of Type 1 diabetics after several years on insulin therapy (Cryer, 
2008). Insulin therapy was implicated in an estimated 13.9% of emergent 
hospitalizations for ADEs (HHS, 2014). Hypoglycemia was cited as the cause for an 
estimated 14 per 1000 patients and 298,000 ED visits in 2009 in the population of adult 
insulin requiring diabetics (CDC, 2013). It is also indicated that 2-4% of diabetics die 
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each year from hypoglycemia; however, more recent estimates indicate that up to 10% of 
deaths of Type 1 diabetics are the result of hypoglycemia. It is surmised that, although 
profound hypoglycemia can cause brain death, most episodes of fatal hypoglycemia are 
the result of cardiac arrhythmias (Seaquist et al., 2013).  An estimated one in five Type 1 
diabetics and two in ten Type 2 diabetics suffer impaired awareness of hypoglycemia 
(Robertson, 2012). The statistics regarding the magnitude of hypoglycemia are likely 
underestimated as most hypoglycemic events are not reported. The incidence of severe 
hypoglycemia may be more reliable than hypoglycemic events in general due to need for 
intervention from an outside source; however, these estimates are also considered under-
represented. Inconsistent application of definitions across healthcare systems and 
epidemiological studies make it difficult for surveillance and comparisons to take place. 
Diabetic patients afflicted by repeated hypoglycemia may also be less likely to report 
events due to fear of activity restrictions, such as employment or driving privileges, thus 
skewing actual data regarding the phenomena. (Wild et al., 2007). The phenomenon of 
hypoglycemia does not typically garner the attention that it deserves from an 
epidemiological viewpoint.  
 Psychosocial Implications. The experience of hypoglycemia produces anxiety in 
individuals with insulin requiring diabetes and their families. Repeated hypoglycemic 
events, or even one severe event, has the potential to inflict traumatic stress in an insulin 
requiring diabetic. Along with the physical manifestations of hypoglycemia and the 
anxiety associated with the fear of developing complications from hyperglycemia long 
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term, the insulin requiring diabetic with hypoglycemia often develops a loss of internal 
locus of control and begins to experience reliance on others, social stigma and isolation, 
marital discord and a deterioration in the concept of self (Wild et al., 2007). 
Hypoglycemia is known to negatively influence an insulin requiring diabetic’s self-
efficacy (Erol & Enc, 2011).    
 Safety implications.  Iatrogenic hypoglycemia is a major obstacle for insulin 
requiring diabetics and poses distinct safety risks to the individual experiencing the 
event and the individual(s) that surround that person. Hypoglycemic events have been 
associated with injuries due to falls, while using equipment, and motor vehicle accidents, 
to name a few. Hence, not only does hypoglycemia risk the health and well-being of the 
individual, it can directly impact upon the health and well-being of those who come in 
contact with the individual in the community setting.   
Financial Implications.  Hypoglycemia places an additional financial burden on 
individuals, families, and the healthcare system. Estimating the financial burden has 
historically been difficult in the United States due to under-reported episodes and broad 
differences in payer systems across the continuum (Quilliam, Simeone, Ozbay, & Kogut, 
2011). Financial burden can be experienced in the form of the need for additional durable 
medical equipment (DME), such as blood glucose testing strips, lost work days, 
reduction in productivity, and increased health care related expenditures. Hypoglycemia 
management accounts for up to 13% of all out of pocket costs related to DM. An 
estimated 30% of insulin treated diabetics experience hypoglycemia at work and up to 
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10% of diabetics leave work or stay home from work due to a hypoglycemic event. 
Hypoglycemia reduces productivity as the average loss of work time for a hypoglycemia 
event is 9.9 hours overall. Absenteeism and tardiness rates are higher in insulin requiring 
diabetics due to hypoglycemia. Employers lose an estimated $1939.06 to $2986.28 per 
patient yearly due to the impact of hypoglycemia. The average cost for hypoglycemia 
management in the United States for individuals is an estimated extra $35.36/ month due 
to the need for additional groceries, DME, and transportation (Brod, Christensen, 
Thomsen, & Bushnell, 2011).  
Fear of Hypoglycemia (FoH).  Hypoglycemia is common, unpredictable, and 
worrisome to the insulin requiring diabetic. Insulin requiring diabetics must constantly 
modify their habits in an effort to balance between the avoidance of hypoglycemia and 
the long term consequences of hyperglycemia. Paradoxically, the modality that is 
indicated as life sustaining, i.e. insulin, becomes a source fear (Erol & Enc, 2011). The 
immediate, significantly unpleasant, and sometimes life-altering effects of hypoglycemia 
are much more tangible to the insulin requiring individual than the risks of developing 
long term diabetic complications. Hence, insulin requiring diabetics tend to develop FoH 
and utilize maladaptive coping strategies to avoid ADEs. This avoidance frequently 
triggers behavioral changes that manifest in the form of hyperglycemia. FoH, 
accompanied by the hyperglycemia associated with the inappropriate avoidance of either 
euglycemia or hypoglycemia, compromises metabolic control and increases the risks of 
diabetic complications while at the same time inducing psychological distress (Wild et 
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al., 2007). This cyclical chain of events desensitizes the diabetic individual to more 
extreme glycemic variations, thus increasing the associated risks of both hypoglycemia 
and hyperglycemia. The FoH leads to chronic anxiety, mood disorders, depression, 
dependency, loss of control, reduced productivity, and disruption of personal 
relationships (Seaquist et al., 2013).  
 Interventions.  The ADA (2014) emphasizes that the prevention of hypoglycemia 
is deemed a critical element in adequate diabetes management.  Ongoing education and 
support are critical to the prevention of complications. Comprehensive diabetic 
management strategies involve inquiry regarding hypoglycemia, including the severity, 
frequency, and cause. There is evidence that interventions, such as blood glucose 
awareness training (BGAT), can reduce levels of fear and improve diabetes management. 
Diabetes education is considered one of the most useful and cost-effective methods to 
promote coping techniques and help insulin requiring diabetics to gain an increased 
sense of control over hypoglycemia (Wild et al., 2007). Diabetes education regarding 
hypoglycemia prevention, detection, and treatment is also noted to assist diabetics on 
insulin with making positive behavioral changes to adapt and improve self-care abilities 
(Erol & Enc, 2011). Shared decision making, collaborative goal setting, and education 
empower patients with insulin requiring diabetes and allows them to successfully 
engage in problem solving (HHS, 2014). There is currently less available research on the 
influence of self-management education on FoH, but there is clear evidence that diabetes 
education improves outcomes. Systems must determine new surveillance methods to 
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provide consistent manners of reporting hypoglycemia to assess the impact of 
interventions (Seaquist et al., 2013).  
Problem Statement 
 Insulin therapy is a life sustaining or life preserving therapy for the treatment of 
DM. Insulin therapy commonly results in iatrogenic hypoglycemia of varying severity. 
Iatrogenic hypoglycemia triggers a FoH in adult insulin requiring individuals with DM 
thereby increasing the risk of repeated hypoglycemia, hyperglycemia, and suboptimal 
long term health outcomes. Strategies that reduce FoH and promote self-efficacy for the 
prevention, detection, and treatment of hypoglycemia are needed to illustrate how 
evidence based research can be translated to real world clinical settings successfully.   
Question Guiding Inquiry (PICO-T) 
 The original prognosis PICO-T question guiding scholarly inquiry for the 
proposed EBP was, “Does individualized self-management education influence the FoH 
and IoH in adult patients diagnosed with insulin requiring diabetes mellitus within 4 
weeks?  The PICO-T was revised to a time span of four weeks due to the time constraints 
of the program.  The PICO-T format was derived from direction from Melnyk & Fineout-
Overholt (2011) and New York University (2014).   
Population.  The population of interest for the EBP included adult, insulin 
requiring diabetic patients evaluated in a single outpatient endocrinology office in 
Northeastern Pennsylvania. Inclusion criteria for participation in the project included: 
English speaking, adult over age 18 years, diagnosis of insulin requiring DM, able of 
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performing self-blood glucose monitoring (SBGM), an ability to read above a 6th grade 
level, and access and willingness to participate in telephone follow up.  Exclusion criteria 
included: age under 18 years, gestational diabetes, non-insulin requiring DM, cognitive 
impairment, inability to provide informed consent, inability to read above a 6th grade 
reading level, inability to participate with telephone follow up, refusal or inability to 
perform SBGM, or reliance on another person for the administration and determination 
of insulin therapy.  
 Intervention.  The intervention for the EBP entailed the review of a developed 
take-home hypoglycemia psychoeducational tool (Appendix A) by participants for 
application to daily life after the completion of the FH-15 Survey (Appendix B) and a 
brief survey question regarding self-reported IoH (Appendix C).  
 Comparison.  The comparison between pre-education and post-education FH-15 
surveys and question regarding the incidence of self-reported hypoglycemia was made. 
No control group was utilized for the project.  
 Outcome.  The anticipated outcomes of the EBP were a reduction in FoH and 
self-reported IoH within the four weeks following the intervention. The FH-15 survey 
and IoH question were administered at baseline and four weeks post intervention.  
Time.   The time frame for the EBP implementation was anticipated to be 10 
weeks. The final outcome measures were administered 4 weeks after the time of the 
intervention.  
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System and Population Impact 
 Iatrogenic hypoglycemia is a significant problem for insulin requiring diabetics. It 
serves as a major barrier to the achievement of adequate and consistent glycemic control 
thus increasing the risk of complications due to hypoglycemia and hyperglycemia. The 
ramifications of hypoglycemia are far reaching and impact upon individuals, families, 
communities, and healthcare systems. There are extensive risks to the health and well-
being of the identified insulin requiring diabetic population from hypoglycemia. There 
are also significant psychosocial risks to the families of insulin requiring diabetics and 
safety risks to members of the diabetic’s community from hypoglycemia. Furthermore, 
the financial impact associated with hypoglycemia is considerable in an era where 
resource dollars for allocation are scarce.  
Purpose, Aims, and Objectives 
 The purpose of the EBP in addressing the fear of hypoglycemia in insulin users 
was to demonstrate how research can be translated and applied to a real world setting. It 
was the intention of the investigator that this EBP is the first in a series of quality 
improvement initiatives meant to impact upon individual patients and the investigators 
organization. The project was intended to promote and improve adequate self-
management skills and internal locus of control in individual insulin requiring diabetics 
by reducing FoH and the incidence of hypoglycemia. It was also intended to make an 
impact at an organizational level through the dissemination of evidence based 
information throughout the organization to drive changes in documentation, practice 
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standards, and data collection for further evaluation. Insulin requiring diabetics that are 
armed with the knowledge of how to prevent, detect, and treat hypoglycemia 
appropriately are anticipated to achieve better long term outcomes. Interventions aimed 
at autonomy supported self-management of diabetes have the distinct potential of 
improving the health and well-being of the insulin requiring adult population and in 
reducing health care expenditures across the continuum.  
Conclusion  
 The need to address the phenomenon of hypoglycemia and its related 
consequences is often overshadowed in the discussion of diabetes and considered 
secondarily to hyperglycemia; but clinicians must remain diligent in their efforts to 
combat this complication. Patient centered approaches in addressing the phenomena of 
hypoglycemia can aid in better quality of care for the insulin requiring diabetic 
population.  
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Chapter Two: Review of the Literature and Evidence 
The critical analysis of the relevant literature assists in developing a framework 
as to how a body of evidence relates to the topic of interest. The synthesis of evidence is 
not merely intended to reiterate references or citations, but is meant for identifying 
evidence that provides a standard for best practices and stimulates future inquiry for 
translational research. The developed clinical question, “Does individualized self-
management education influence the FoH and the IoH in adult patients diagnosed with 
insulin requiring diabetes mellitus within 4 weeks?” is the driving force behind the 
assessment of the literature. The purpose of this chapter is to provide a literary 
framework that illustrates the need for evidence based practice changes that support 
patient centered diabetes care. The results of the project were intended to add to the 
body of growing evidence that supports quality care improvement initiatives for diabetic 
patients, mitigate safety risks that are associated with iatrogenic hypoglycemia, and 
empower patients by minimizing FoH. The presented synthesis of the evidence within 
the literature supported the need for inquiry to narrow research gaps and illustrated the 
significance of devising interventions that address the phenomena of interest. 
Methodology 
 The determination of a logical search strategy was imperative for data 
organization and defense of the interpretation of the results once the review of the 
literature and evidence was completed. (Moran, Burson, & Conrad, 2014). Hence, a 
comprehensive review of the relevant literature was performed by thoroughly searching 
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the following data bases: Academic Search Primer, Cumulative Index of Nursing and 
Allied Health Literature (CINAHL), Cochrane, Education Resource Information Center 
(ERIC), Healthsource, MEDLINE, PubMed, and Science Direct. The GOOGLE search 
engine was also intermittently accessed to broaden search capabilities thus ensuring 
access to as much information on the subject as possible. Database searches were 
restricted to 2004-2015 in an attempt to yield the most recent available data. Cross 
referenced landmark studies outside of the aforementioned date range or data in support 
of the conceptual framework of the literature review were summarized as their inclusion 
was felt to be crucial for providing context to the phenomena of interest.   
Keywords and Medical Subject Heading (MeSH) terminology used to procure 
relevant literature included: diabetes, insulin, insulin requiring, hypoglycemia, fear of 
hypoglycemia, prevention, detection, patient education, autonomy supported patient 
education, self-management, blood glucose awareness training, individualized education, 
and shared decision making,  Boolean phrases such as “and”, “or” and “not” were used in 
combination with keywords and literature involving adolescents, pediatrics, pregnant 
woman, or diabetics treated exclusively with oral pharmacological agents were excluded.
 Data extraction used the aforementioned keywords and phrases yielded varying 
amounts of data at the times the searches were performed. An initial search for 
hypoglycemia yielded 49,408 results. The inclusion of self-management yielded 288, and 
variation of the date range led to the discovery of 237 results. The exclusion of 
adolescents and pediatrics reduced the results to 223. Inclusion of insulin yielded 97 
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results which made the topic exceptionally more manageable. A combined search with 
FoH offered 15 results and narrowed the topic of inquiry to blood glucose awareness 
training as a viable area of study and provided a randomized controlled trial regarding 
the topic of interest. A continued search of the literature regarding autonomy support 
procured 841 results. The combination of hypoglycemia with this phrase yielded no 
results, however, a combination with diabetes resulted in 10 articles. Shared decision 
making produced 227 results and was able to be focused to 6 articles when the term 
hypoglycemia was added. Individualized care was searched resulting in 185 articles; this 
was narrowed to 36 articles with the inclusion of the keywords patient education and 
the exclusion of pediatrics and adolescents. The GOOGLE search engine was utilized to 
access alternative sites that provided full text access of the discovered information and to 
access the most up to date clinical practice guidelines in order to augment the search of 
the relevant literature.  
The most recent data evaluating the phenomena of interest was searched until no 
new recognizable data was noted of relevance within the date range and a saturation 
point of common evidence was reached. Levels of evidence included in the search for 
relevant literature included: systematic reviews, randomized controlled trials, cohort or 
case control studies, qualitative and descriptive studies, and expert opinion publications.   
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Findings 
 Diabetes and the need for insulin.  The ADA (2014) defines diabetes as a group 
of metabolic disorders stemming from defects in insulin secretion, insulin action, or both. 
The disorder is characterized by chronic hyperglycemia. Chronic hyperglycemia in 
diabetes is associated with long-term damage to multiple organs, specifically including 
the eyes, kidneys, nerves, heart, and blood vessels. Complications of diabetes include: 
retinopathy and a potential for blindness, nephropathy with progressive renal failure, 
peripheral neuropathy and a risk of lower extremity ulceration and/or amputation, 
autonomic neuropathy with gastrointestinal, genitourinary, and cardiovascular (CV) 
symptomatology, and atherosclerosis of coronary, peripheral, and cerebrovascular 
vessels. The assessment of glycemic control is performed through two primary 
techniques: self-blood glucose monitoring (SBGM) and measurement of the glycosylated 
hemoglobin (HbgA1C). The results of SBGM performed by the patient using a 
glucometer provides assistance to patients in guiding decision making in self-
management and assists HCPs in ensuring that ongoing instruction is provided and 
regular evaluation of the effectiveness of the treatment plan is completed (ADA, 2014).   
The HbgA1C measurement reflects average glycemia over several months, correlates with 
mean plasma glucose values, and is a strong predictor of risk associated with diabetic 
complications. The HbgA1C provides feedback to patients and providers as to the need 
for additional risk reduction and evaluates the effectiveness of the current treatment plan 
(ADA, 2014). Landmark clinical trials have demonstrated the importance of intensive 
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glycemic control in the prevention of diabetic complications related to chronic 
hyperglycemia; however, the application of intensive therapy comes with a cost.  
Glycemic control is fundamental to diabetes management (ADA, 2014). The most 
noteworthy trials that provided the evidence for current standards of care that guide 
clinical decision making on diabetes management include: the Diabetes Control and 
Complications Trial (DCCT), the Epidemiology of Diabetes Interventions and 
Complications (EDIC) trial, the United Kingdom Prospective Diabetes Study (UKPDS), 
and the Kumamoto study.  
 The DCCT was a large prospective randomized controlled trial (RCT) released in 
June of 1993 at the annual Scientific Sessions meeting of the ADA and was sponsored by 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the 
National Institutes of Health (NIH). This landmark study proved conclusively that 
intensive control of blood glucose in individuals with Type 1 diabetes could significantly 
reduce the incidence of retinopathy, nephropathy, or neuropathy, otherwise known as 
diabetic microvascular disease.  The study involved 1441 Type 1 diabetics between the 
ages of 13 and 39 years in 29 medical centers in the United States and Canada. The 
duration of diabetes was between 1 and 15 years and each participant was required to 
have early to no signs of diabetic eye disease. This study compared the effects of 
standard, HbgA1C 7-7.9%, versus intensive control, HbgA1C <6%, on the complications 
of diabetes.  The study demonstrated that intensive glycemic control reduced the risk of 
retinopathy by 76%, nephropathy by 50%, and neuropathy by 60%. The most significant 
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side effect of intensive treatment was an increase in the risk for hypoglycemia and the 
recommendation to implement intensive therapy is meant to be exercised with caution 
with consideration to the risk-benefit ratio (The Diabetes Control and Complications 
Trial Research Group, 1993).  
 EDIC was a landmark observational follow-up study to DCCT which continued 
to study more than ninety percent of the DCCT participants, or 1394 individuals. EDIC 
evaluated the incidence and predictors of CV, or macrovascular, disease in addition to 
microvascular disease. It also examined the impact of intensive versus standard glycemic 
control on quality of life and on cost effectiveness. EDIC demonstrated intensive 
glycemic control reduced the risk of any CV disease event by 42% and non-fatal 
myocardial infarction, cerebrovascular accident, or death from CV causes by 57%. EDIC 
was also beneficial in determining that the difference in outcomes between the intensive 
and control groups is persistent for as long as ten years. The prolonged and beneficial 
effects of intensive therapy, or the negative effects of standard therapy, influence the 
development of future risks.  The preceding trend was coined as imprinting or metabolic 
memory (The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group, 2005).  
 The UKPDS Study aimed to determine the effect of intensive versus conventional 
glycemic control on the incidence of diabetic complications with a secondary aim of 
assessing the differences between treatments. This RCT evaluated patients utilizing 
both oral agents and insulin for the treatment of diabetes. The study was the largest and 
22 
 
 
 
  
 
longest study ever undertaken in diabetes and involved participation from over 7600 
patients in 23 centers across the United Kingdom. The UKPDS demonstrated that any 
improvement in glycemic control and blood pressure reduced diabetic related 
complications. An increased risk in hypoglycemia was also noted (King, Peacock, & 
Donnelly, 1999).   
 The Kumamoto Study, a RCT examining whether intensive glycemic control 
could decrease the frequency and severity of microvascular complications in Type 2 
diabetics was released in 2000.  This prospective study of 110 participants utilizing 
insulin therapy demonstrated that intensive glycemic control can delay the onset and 
progression of the early stages of diabetic microvascular complications in Japanese 
patients with Type 2 diabetes. This study also demonstrated an increased risk of 
hypoglycemia, but this was noted to be to a lesser degree and severity than previously 
noted in the DCCT trial (Shichiri, Kishikawa, Ohkubo, & Wake, 2000). It is obvious 
from the volume of evidence surrounding the treatment of diabetes that the reduction of 
long term risks associated with hyperglycemia are moderated through the attainment of 
intensive glycemic control. This reduction in risk, however, comes with the price of an 
increased risk of hypoglycemia as noted in the evidence.   
Diabetes involves multiple pathogenic processes ranging from autoimmune 
destruction of the pancreatic β-cells and insulin deficiency to a diminished tissue 
response to insulin and insulin resistance. The etiology of diabetes predominantly falls 
into two broad categories; Type 1 diabetes, caused by absolute insulin deficiency, and 
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Type 2 diabetes, caused by a combination of insulin resistance and an inadequate 
compensatory insulin secretory response. The severity of the underlying metabolic 
abnormalities can remain dynamic through the course of the disease process, but it is the 
present degree of hyperglycemia at a specified period in time that reflects the severity of 
the underlying metabolic process and determines the treatment. This complex, chronic 
illness requires a multi-factorial approach to management in order to prevent the 
consequences of hyperglycemia. Although modalities such as education and 
improvement in lifestyle habits can positively influence outcomes, historically, insulin 
therapy is often times unavoidable. This is predominantly due to the acute nature of 
Type 1 diabetes or the progressive nature of Type 2 diabetes, despite adherence to 
lifestyle modification or other pharmacological agents. Insulin therapy thus becomes a 
life-preserving, and in many cases, a life-sustaining treatment.  
The use of insulin therapy is associated with a higher risk of iatrogenic 
hypoglycemia. Although extrapolation of epidemiological evidence from DCCT and 
UKPDS validates a curvilinear relationship between Hemoglobin A1C and the 
development or progression of microvascular complications, on a population level, the 
greatest number of complications will be averted by taking the most uncontrolled 
patients to fair/good control. Additional lowering of Hemoglobin A1C below seven 
percent is associated with a continued risk reduction; however, the absolute risk 
reductions become much smaller as the Hemoglobin A1C decreases toward the intensive 
goal. It is of importance to note that the risks of lower glycemic targets used to avert 
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complications from hyperglycemia may outweigh the potential benefits on a population 
level due to the risk of iatrogenic hypoglycemia (ADA, 2014).  Evidence from landmark 
studies, such as Action in Diabetes and Vascular Disease: Preterax and Diamicron MR 
Controlled Evaluations (ADVANCE), Action to Control Cardiovascular Risk in Diabetes 
(ACCORD), and the Veterans Affairs Diabetes Trial (VADT), indicate an increase in the 
rate of serious hypoglycemic events in the intensive control groups as compared to the 
standard control groups (ADA, 2014).  
The ADVANCE trial was a factorial, multicenter, RCT with a recruited 11, 140 
participants evaluating both blood pressure and glucose. This study took place from 
2001-2008 and included adults with Type 2 diabetes aged 55 years or older, with an 
increased risk of CV disease. Participants in the glucose arm were randomized to either 
an intensive modified release gliclazide based glucose lowering regimen or a standard 
guidelines-based glucose lowering therapy with follow up estimated to be for an average 
five to six years. The primary outcomes of the study were major microvascular and 
macrovascular complications. The aim of ADVANCE was to see if treatment to lower 
glucose levels more tightly than usual would reduce the risk of all complications in 
adults with Type 2 diabetes. Severe hypoglycemia, hypoglycemia requiring outside 
assistance, was more frequent in the intensive control group than in the standard group 
with 150 patients, or 2.7%, having at least one episode of severe hypoglycemia compared 
to 81 patients, or 1.5%, in the standard group with a hazard ratio of 1.86 and P <0.001. 
Minor hypoglycemia was also more frequent in the intensive control group with 120 
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events per 100 patients per year versus 90 events per 100 patients per year with standard 
control. This study also demonstrated that intensive therapy had no significant effect on 
reducing CV disease (The ADVANCE Collaborative Group, 2008).  
 The ACCORD trial was designed to determine the best ways to decrease the risk 
of macrovascular disease in Type 2 diabetics. The study was intended to last 
approximately eight years and recruit 10,000 participants. This randomized, multicenter, 
double 2 x 2 factorial study from two countries was funded by the National Heart, Lung, 
and Blood Institute in collaboration with the NIDDK, the National Eye Institute, and the 
CDC. Patients with a median Hemoglobin A1C of 8.1% were assigned to receive intensive 
therapy or standard therapy. The primary outcome was a composite of nonfatal 
myocardial infarction, nonfatal stroke, or death from CV causes. The trial was 
terminated after a mean of 3.5 years of follow up due to higher mortality in the 
intensively treated groups as compared with the standard treated groups. The primary 
outcome occurred in 352 patients in the intensive therapy group as compared to 371 in 
the standard therapy group. Concurrently, 257 patients in the intensive therapy group 
died as compared to 203 patients in the standard therapy group. Hypoglycemia requiring 
assistance was more frequent in the intensive therapy group with P <0.001. This study 
concluded that the use of intensive therapy did not significantly reduce major CV events 
and actually identified a previously unrecognized harm associated with intensive 
therapy.  
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The limitations of this study included the unaddressed issues of the risks and 
benefits of various approaches to lowering HbgA1C levels and a design that was not well 
suited for determining whether certain subgroups may benefit from intensive therapy. 
Additionally, analyses to determine which aspects of the therapeutic strategy 
contributed to which outcome were not able to be identified or excluded and 
exploration of the data would require additional prospective testing (The Action to 
Control Cardiovascular Risk in Diabetes Study Group, 2008).   
The goal of the VADT trial was to compare the effects of intensive and standard 
glucose control on CV events. This open label RCT targeted poorly controlled Type 2 
diabetics or selected individuals with inadequate responses to oral agents and insulin. 
Participants were required to have had a HbgA1C >7.5%, and the lack of CV events 
during the past six months with a life expectancy of less than seven years. It included 
obese patients with nephropathy and hepatic disease. Patients were randomized 
according to study site, the previous occurrence of a macrovascular event, and current 
insulin use. The most common adverse event was hypoglycemia with significantly more 
episodes in the intensive therapy group than in the standard therapy group in every 
category with P <0.001.  This study concluded that intensive control did not decrease the 
rate of CV events in patients with advanced disease but did increase hypoglycemia risk 
(Duckworth et al, 2009). 
Additionally, in conjunction with the aforementioned landmark trials, a recent 
retrospective cohort study (Khunti et al., 2015) that used data from the Clinical Practice 
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Research Datalink database including all insulin treated patients over 30 years of age 
with a diagnosis of diabetes was published in Diabetes Care. The objective of the study 
was to assess whether there was an association between hypoglycemia, the risk of CV 
events, and all-cause mortality among insulin treated diabetics. A cumulative 13,682 
patients were included in the regression analyses which included 3260 Type 1 diabetics 
and 10,422 Type 2 diabetics. During the course of the study, the proportion of diabetics 
in each group experienced CV events or death at a statistically similar rate, 18% versus 
14% respectively. Death rates were twofold higher in both cohorts for patients with a 
history of CV disease. Basic statistical analysis along with stratified univariate and 
multivariate Cox regression models to estimate the risk of vascular events and mortality 
associated with hypoglycemia and practice level deprivation score as the stratification 
factor were used. This study indicated that patients who experience hypoglycemia were 
at a greater risk of CV events. Patients without a history of CV disease experiencing at 
least one episode of hypoglycemia had a 92% and 50% significantly increased risk of 
composite CV events in both cohorts. The study concluded that, in a nationally 
representative contemporary population, hypoglycemia is associated with an increased 
risk of CV events and all-cause mortality in insulin treated patients and confirms the 
findings noted in the ACCORD trial. It also adds to the body of evidence that supports 
the link between hypoglycemia and CV events in people with Type 1 diabetes. The study 
summarizes the point that CVD remains the primary cause of death in insulin treated 
diabetics; this is largely due to hyperglycemia and pre-existing comorbidities, but the 
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role of hypoglycemia as a contributing factor is still of importance. The study was not 
intended to identify a causal relationship, but to explore the relationship between 
hypoglycemia and CVD. The limitations of the study included the lack of randomization, 
the inability to capture all relevant confounding factors in the database, the 
underreporting of the incidence and severity of hypoglycemia, selection criteria affecting 
the representative quality of the Type 2 diabetes cohort, and inclusion of patients with 
Read Codes in C10+. Identified strengths of the study included a large sample size, 
evaluation in the Quality of Outcomes Framework period, a high quality of a nationally 
representative sample, and a robust approach to multivariate analyses providing a 
broader statistical picture. The implications of the study have a high applicability to the 
phenomena of interest as it confirmed a relationship between hypoglycemia and an 
increased risk of CV outcomes over an extended time frame and indicates that 
hypoglycemia may be a surrogate marker of greater disease burden and thus an indirect 
marker of CV risk. It was the recommendation of the study investigators that HCPs pay 
special attention to insulin treated patients who experience a hypoglycemic event and 
focus their efforts on the reduction of the IoH.   
The most recent statistics available to date from the CDC (2014) estimate the 
incidence of diabetes at 29.1 million people, or 9.3% of the population, in the United 
States as of 2012. Diabetes was ranked as the seventh leading cause of death in the 
United States in 2010, but estimates citing cause of death due to diabetes are considered 
to be underreported. The estimated total cost of diabetes in the United States in 2012 
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was $245 billion. Understanding the epidemiologic magnitude of the phenomena of 
interest requires conceptualizing the fact that an estimated 26% of the 21 million people 
with diagnosed diabetes in the United States are being treated with insulin therapy; this 
equates to over 5 million people on insulin therapy. It becomes a logical conclusion that 
as the population of people with diagnosed diabetes increases, so shall the population of 
patients requiring insulin therapy.  HCPs armed with the knowledge of the impact of 
diabetes on the population as evidenced by the aforementioned statistics are better able 
to comprehend the need for real world practice strategies to improve quality of care for 
diabetic patients, their families, communities, and health care systems. Health care 
providers must also possess the realization that insulin therapy is a method of treatment 
that cannot be averted if sustaining life and preventing long term complications are the 
goals of therapy; but it also needs to be recognized that the implementation of intensive 
glycemic control for the purpose of controlling hyperglycemia cannot outweigh the 
potential risk for hypoglycemia. Hypoglycemia risk is an important consideration in the 
determination of individualized care, the mutual setting of glycemic targets, and is a 
critical determining factor in the management of diabetes to both the patient and the 
HCP.   
The barrier of iatrogenic hypoglycemia.  Iatrogenic, or treatment induced, 
hypoglycemia is considered the greatest limiting factor that precludes the achievement of 
a degree of glycemic control that is considered adequate enough to prevent the long- 
term consequences of diabetes due to hyperglycemia. Iatrogenic hypoglycemia causes 
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recurrent morbidity, has the potential for fatality, compromises physiological and 
behavioral defenses against future events thus resulting  in the cyclical pattern of 
recurrent hypoglycemia, and does not allow for the continued long term maintenance of 
adequate glycemic control across a lifespan with diabetes thus leaving the benefits of 
adequate glycemic control unrealized (Cryer, 2008). Therefore, it is incumbent upon 
health care providers to individualize care for the treatment of hyperglycemia while 
keeping the risk for hypoglycemia in mind as each needs to be balanced for mitigation of 
both short and long term risks to health and well-being.  
 There are multiple sources within the literature that identify iatrogenic 
hypoglycemia as the major barrier to the attainment of adequate glycemic control.  A 
systematic review (SR) by Seaquist et al. (2013) reviewed the available evidence about 
the impact of hypoglycemia on patients with diabetes. The report was formulated 
through a joint effort between the ADA and The Endocrine Society. It contained all 
available new data from recent clinical trials and other studies since the past review of 
information on the subject of hypoglycemia by the ADA and The Endocrine Society and 
was used to update the previous workgroup report. The reviewers did not utilize 
unpublished data but did use expert opinions to develop some conclusions. The review 
was achieved through consensus and served to provide guidance about how new 
information should be incorporated into clinical practice. This SR was instrumental in: 
reconfirming the previous definitions of hypoglycemia in diabetes, reviewing the 
implications of hypoglycemia on both short and long term outcomes, considering the 
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implications of hypoglycemia on treatment outcomes, presenting strategies to prevent 
hypoglycemia, and identifying knowledge gaps that need to be addressed by future 
research.  
Additionally tools were presented for patient use to report hypoglycemia at each 
visit and for HCP use to guide documentation of the counseling provided. The 
workgroup determined hypoglycemia to be defined as a blood glucose <70 mg. /dl and to 
be classified and documented as severe, symptomatic, asymptomatic, probable 
symptomatic, and pseudo-hypoglycemia. The implications of hypoglycemia were 
concluded to be a potential cause of fatality, brain death, or ventricular arrhythmia with 
up to ten percent of all deaths in Type 1 and 2 diabetics caused by hypoglycemia. The 
workgroup also concluded that recurrent episodes of hypoglycemia trigger hypoglycemia 
unawareness and hypoglycemia associated autonomic failure, hypoglycemia impacts on 
cognitive function in Type 1 diabetics, and there is an increased risk of mortality and CV 
disease in diabetic patients. The review elucidated information on special populations, 
such as the elderly, hospitalized and pregnant diabetics, as well as assessed the impact of 
hypoglycemia on quality of life due to FoH and activities of daily living. The workgroup 
concluded that glycemic targets should depend on age, life expectancy, comorbidities, 
preferences, and the assessment how resultant hypoglycemia may impact the patient’s 
life. An individualized treatment plan using a patient centered approach was advised. 
The workgroup stressed the following approaches to decrease the risk of iatrogenic 
hypoglycemia: patient education, dietary intervention, exercise management, medication 
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adjustment, glucose monitoring, and clinical surveillance. The current knowledge gaps 
identified by the SR include: the need for the development of new surveillance methods 
to provide consistent metric collection to determine the epidemiological impact of 
hypoglycemia, the need to investigate which patients are most at risk for hypoglycemia, 
the need to develop new educational strategies to reduce the incidence of hypoglycemia, 
and the need for development of new blood glucose monitoring technologies with 
improved accuracy, ease, reliability, and cost-effectiveness.  
The SR was a review of all published data on the topic of hypoglycemia from 
2005-2012 and the data was evaluated, discussed, and summarized in the consensus 
report. Its findings indicated the importance of hypoglycemia on morbidity and 
mortality, the significance of the prevention of hypoglycemia, and the need for additional 
research to explore the phenomena. The weaknesses of the SR were identified as: its 
inability to empirically define individualized glycemic targets from a public health 
standpoint, the inability to evidence the balance between strict targeting and the goal of 
hypoglycemia prevention, the lack of culturally specific evidence, and the lack of an 
evidence based table. However, despite its limitations, the SR was considered to be 
highly reliable, valid and applicable to the phenomena of interest as it went directly to 
the heart of subject matter and included an extensive review of all available literature in 
combination with the consensus of experts in the field.  
There are two clinical practice guidelines that are worthy of mention in 
addressing the phenomena of hypoglycemia and substantiate the need for the project. 
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These guidelines were derived from available published data from the ADA and The 
Endocrine Society and are addressed individually. The ADA (2014) Standards of Medical 
Care in Diabetes is viewed as an important resource for the health care providers and it 
divulged key clinical practice recommendations based on extensive literature searches 
and updates that are done annually based on the quality of new evidence. The Endocrine 
Society (2009) set forth practice guidelines with the aim of assisting HCPs in evaluating 
and managing diabetes with a particular chapter devoted to hypoglycemia in persons 
with diabetes mellitus.  
The ADA (2014) identified hypoglycemia as a leading factor limiting glycemic 
management of insulin requiring diabetics that was associated with acute harm and 
increased mortality. The ADA mirrored the conceptual approaches identified in Seaquist 
et al (2013) in addressing hypoglycemia prevention. Attention to the prevention of 
hypoglycemia was considered a critical component of diabetes management. The 
practice guideline strategically provided the instructions that individuals should be 
queried regarding hypoglycemia at each encounter, advised on proper treatment and 
SBGM, provided glucagon if at significant risk, have ongoing assessment of cognitive 
function to stratify risk, and should be provided individualized treatment goals based on 
risk of hypoglycemia.  
The ADA clinical practice guidelines contained an executive summary that 
addressed aspects of medical care required for individuals with diabetes. An analysis of 
all relevant literature, both past and present, was analyzed to update the guidelines. The 
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ADA was instrumental in developing, analyzing, and disseminating care standards and 
its Professional Practice Committee was a panel of multidisciplinary experts charged 
with the routine review and revision of evidence based standards. ADA clinical practice 
guidelines provide sound evidence for decision making. Determination of the reliability 
and validity of the guideline was evaluated using the Appraisal of Guidelines for 
Research and Evaluation (AGREE) instrument (2001). The scope and purpose of the 
guideline provided clearly defined objectives, specifically covered clinical questions, and 
defined patient populations for application. Relevant professional groups and target 
users were identified as stakeholders and performance measures were indicated. The 
rigor of development was considered worthy as: systematic methods were identified to 
search for the evidence, the criteria for selecting evidence was clearly defined, the 
methods for formulating recommendations were clearly defined, risk/benefit/side effects 
were considered, recommendations were linked to evidence, external review was 
internally and externally performed and the procedure for continued revision was 
described. The guideline was specific and unambiguous. Management options and key 
recommendations were identified along with a description of criteria for monitoring. 
Cost was mentioned, but organizational barriers and cost implications were not 
specifically described. The editorial independence of the guideline was sound and 
conflicts of interest were identified. The guideline was considered to be highly reliable, 
valid and supported by the highest levels of evidence available. It was applicable to the 
35 
 
 
 
  
 
project as it addressed the issue of hypoglycemia and provided evidence based support 
for the provision of care and the selected clinical problem.  
The Endocrine Society (2009) also set forth clinical practice guidelines regarding 
hypoglycemia in their publication Evaluation and Management of Adult Hypoglycemic Disorders. 
The practice guideline included the background for iatrogenic hypoglycemia and 
identified hypoglycemia as the limiting factor in achieving adequate glycemic 
management of diabetes. It was estimated that until the prevention and/or cure of 
diabetes is achieved, the problem of hypoglycemia cannot be solved. Insulin and 
secretagogues were identified as the primary offenders that trigger iatrogenic 
hypoglycemia. Hypoglycemia in the insulin requiring diabetic patient is often considered 
a fact of life with the average patient with Type 1 diabetes experiencing two episodes of 
symptomatic hypoglycemia weekly and thousands over a lifetime along with an 
estimated one episode of severe hypoglycemia, often with seizure or coma, per year. An 
estimated two to four percent of Type 1 diabetics are known to die from hypoglycemia. 
The United Kingdom Hypoglycemia Study, as cited in the guideline, reported that in 
patients treated with insulin for less than 2 years or more than 5 years, the prevalence of 
severe hypoglycemia was 7% and 25% with an incidence of 10 and 70 episodes per 100 
patient years respectively. Thus the risk of hypoglycemia is much lower in the first years 
of insulin therapy and substantially increases later in the course of the disease.  It is also 
estimated that hypoglycemia is grossly underreported. Hypoglycemia was not a primary 
outcome of landmark clinical trials and the extent of data collection regarding 
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hypoglycemia is highly variable. For example, hypoglycemia event rates in UKPDS were 
not known. Insulin trials in Type 2 diabetics are often undertaken immediately after 
transition to insulin from oral agents and earlier in the disease state. Additionally, 
therapeutic goals in clinical trials are often different than those agreed upon in real life 
clinical situations. These points demonstrate the need to consider the evidence from a 
prospective, population based focus. Donnelly et al, as cited in the clinical practice 
guideline, indicated that overall the hypoglycemia event rates in insulin treated Type 2 
diabetes were approximately one third of those in patients with Type 1 diabetes. 
Population based studies from hospital regions with known Type 1 and Type 2 diabetes 
incidences demonstrated event rates for severe hypoglycemia requiring emergency 
treatment in insulin requiring Type 2 diabetics was 40% and approximately 100% of 
those in Type 1 diabetes. Interestingly, because the prevalence of Type 2 diabetes is 
approximately 20-fold greater than that of Type 1 diabetes, and because most patients 
with Type 2 diabetes eventually require insulin therapy, this data suggested that most 
episodes of hypoglycemia occur in Type 2 diabetics.  
The Endocrine Society guidelines indicated the following recommendations: 
persons with diabetes should become concerned about the possibility of developing 
hypoglycemia when SBGM is falling rapidly or is no greater than 70mg. /dl. Therapeutic 
glycemic goals should be the lowest mean glycemia that can be achieved safely in a given 
patient at a given point in the progression of that individual’s diabetes and the 
prevention of hypoglycemia in diabetes involves addressing the issue at each encounter. 
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Making adjustments based on review and application of the principles of intensive 
glycemic therapy and consideration of known hypoglycemia risk factors is needed if 
hypoglycemia is present. Conventional risk and those indicative of compromised 
defenses against hypoglycemia should be considered in patients with recurrent 
iatrogenic hypoglycemia and urgent treatment of hypoglycemia should be accomplished 
by ingestion of carbohydrates or by parenteral glucagon.  
The guideline was evaluated using the AGREE instrument for critical appraisal. 
The guideline was inclusive of the aspects of medical care required for the treatment of 
adult insulin requiring diabetics and was a compilation of evidence derived from SRs, 
expert consensus, and RCTs. No significant weaknesses were evident and the guideline 
provided sound evidence for decision making. The guideline was felt to be reliable and 
valid. The scope, purpose, objectives, clinical questions, and patient populations were 
specifically covered, defined and described. Stakeholder involvement included relevant 
professional groups, target users were identified. Performance measures were indicated. 
The rigor of development was felt to be adequate based on: identification of systematic 
methods to search for the evidence, defined criteria for evidence selection, and defined 
methods for formulating recommendations. Rigor was also adequate due to the 
consideration of risks, benefits, and side effects. Internal and external review was 
performed and procedures for continued revision described. The clarity and presentation 
were satisfactory as the guideline was specific and unambiguous. Management options 
were clear and key recommendations and criteria for monitoring were described. Cost 
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was mentioned, but organizational barriers and implications of cost were not specifically 
described. The guideline was editorially independent with conflicts of interest identified. 
The guideline contained high levels of compiled evidence which lent credence to its 
reliability and validity. It had high applicability to the project as it dealt directly with 
developing the framework for the conceptualization of the project.  
Although not defined traditionally as a SR or clinical practice guideline per se, 
HHS (2014) developed a National Action Plan for Hypoglycemic Safety. The plan 
indicated hypoglycemic agents were one of the drug classes most frequently associated 
with ADEs in both inpatient and outpatient settings with nearly all cases of 
hypoglycemia considered preventable. The plan called for more effective surveillance of 
hypoglycemic events and identification of insulin as a high alert medication to health 
care providers. It remains challenging to compare hypoglycemia event studies or to 
quantify the phenomenon of hypoglycemia as there is inconsistent application of minor 
and severe hypoglycemic event definitions across post-marketing and epidemiological 
studies. Data cited in the plan indicated that approximately one quarter of all patient 
safety incidents involving insulin resulted in patient harm and insulin may be implicated 
in 33% of all medication error related deaths. Action planning also called for HCPs to 
utilize best practice standards involving: individualized target setting, provision of 
patient education, order standardization and continuous risk assessment. HCPs must 
acknowledge patient risk factors associated with a higher risk for hypoglycemia 
including: Body Mass Index, cachexia, age, advanced CV disease, advanced malignancy, 
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renal disease, hepatic disease, compliance, and health literacy. The action plan identified 
a four pronged approach for use in reducing patient harm from ADEs involving: 
surveillance, prevention, incentives and oversight, and research. The plan utilized strong 
evidence based data and identified strategies and specific actions for policymakers, 
professionals, and organizations in addressing hypoglycemia risk. The action plan 
supported the American Association of Colleges of Nursing (AACN) Essentials of 
Doctoral Education for Advanced Nursing Practice (2006) by including: scientific 
underpinnings, leadership for quality improvement, evidence based practice, information 
technology, policy activism, collaboration, clinical prevention and population health, and 
advanced nursing practice. The amassed evidence supporting the recognition of 
iatrogenic hypoglycemia as a major limitation to the attainment of a degree of glycemic 
control substantial enough to prevent complications from hyperglycemia was well 
established in the literature.  
 The phenomena of the Fear of Hypoglycemia (FoH).  The discussion of 
relevant evidence to this point has set the stage for the introduction of the focal 
phenomenon of interest that served as the stimulus for the project.  It has been discussed 
that diabetes is a prevalent metabolic disorder in which attention to strict glycemic 
control reduces complications from hyperglycemia and that insulin therapy is often 
required due to the progressive nature of the disease. Insulin requiring patients are at 
higher risk for repeated hypoglycemia. The use of insulin therapy can be problematic for 
most patients as they try to actively manage their diabetes and balance the need to avoid 
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the acute effects of hypoglycemia with the long term complications of hyperglycemia. 
The immediate and tangible consequences of hypoglycemia produce more noticeable 
concerns to the patient than the potential poorly envisioned future health problems 
(Wild et al., 2007). FoH is a complex phenomenon that is still not yet fully understood.  
 The fear of hypoglycemia and its impacts.  FoH can occur in varying degrees 
and a general consensus definition of the phenomenon has yet to be established. 
Nevertheless, FoH is viewed as the undesirable emotional response triggered by the 
belief that a low blood glucose is a threat. It is completely rational and justified to state 
that some degree of caution and concern regarding the development of hypoglycemia and 
its implications is both adaptive and protective considering the nature of diabetes and 
the previously discussed statistical evidence regarding hypoglycemia in general,. FoH is 
unlike other phobias as it not irrational given the likelihood of experiencing 
hypoglycemia. However, FoH for the contextual purposes of this literature review is 
determined to be a maladaptive, excessive fear that can become problematic and 
disruptive to the diabetic plan of care (Gonder-Frederick, 2013). The presence or absence 
of FoH has the potential to be a problem when encountered in clinical practice. 
Inappropriately heightened levels of FoH are maladaptive as compensatory avoidance of 
near normal euglycemia or overcompensation when treating hypoglycemia or low normal 
euglycemia occurs. Alternatively, inappropriately low levels of FoH in individuals 
deemed to be high risk for hypoglycemia can be just as maladaptive as denial or 
avoidance of the risk can occur. It has been previously noted in this literature review that 
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hypoglycemia frequently becomes a part of life for the diabetic requiring insulin therapy; 
but when the FoH develops, it further complicates the diabetic patient’s self-
management and plan of care.  
Two individual systematic reviews of the relevant literature regarding the topic 
of FoH were analyzed for better comprehension of the subject. Wild et al. (2007) 
provided a critical review of the literature on FoH. The aim of the review was to integrate 
existing research on FoH and discuss its implications for diabetes management and 
patient education. The literature review utilized MEDLINE and EMBASE with studies 
limited to English, published from 1985-2007 and included the review of 301 abstracts 
with 273 exclusions due to non-relevance. Finally, twenty eight papers and six additional 
articles were reviewed regarding the FoH and the negative consequences associated with 
hypoglycemia. Selection and pooling strategies were identified and actual results 
reported. The findings of the review concluded that there was sufficient evidence that 
the FoH has a negative impact on diabetes management, glycemic control, and health 
outcomes. The SR also discussed strategies for reducing the FoH and gaps in the current 
research. It indicated that there was strong evidence that the FoH exists, but there was 
less available evidence as to how it directly affected management behaviors. The 
availability of the data was felt to be negatively influenced by the suspected 
underreporting of hypoglycemia by patients and poor recognition by health care 
providers. The SR was considered valid and reliable with the notation that missing data 
may be due to underreporting. The SR concluded that there is a need for further 
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investigation of the empiric evidence regarding FoH. This is directly applicable to the 
area of inquiry. Wild et al (2007) indicated that FoH is particularly prevalent in patients 
who have been exposed to severe hypoglycemia. There was also an issue with consistent 
measurements of FoH and the need to determine why fear is greater in some individuals 
than in others. The authors signified that FoH triggering compensatory maladaptive 
strategies was an area of interest that has not received the scientific attention that it 
deserves. The evidence presented in the SR provided the basis for the conclusion that 
FoH may motivate some diabetic individuals to inappropriately prevent hypoglycemia 
and thus compromise metabolic control; however, the complexity of the interacting 
variables that comprise the issue make determination of causality very difficult. 
Undoubtedly, this was an area of concern based on the current recommendations 
regarding the management of hyperglycemia and the need for strict glycemic control.  
Gonder-Frederick (2013) provided a comprehensive review of the available data 
on the topic of FoH. The purpose of the SR was to review the current literature on FoH 
and its impact on quality of life and clinical outcomes in people with diabetes and their 
families. Overall, the level of evidence provided in the narrative of the SR was considered 
to be reliable and valid upon evaluation of the 75 references associated with the SR. 
However, the author did not specifically identify selection criteria or pooling strategies. 
The objective of the review, interventions to address the issue, and strategies to address 
future research due to gaps in knowledge were addressed. It was implied that all relevant 
data on the topic of FoH was reviewed, but this was not implicitly stated. Data 
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extraction was inconsistently defined and the use of tables to illustrate data collection 
strategies was underdeveloped. There was no use of tables illustrating compiled study 
results despite summarized results. Gonder-Frederick did compellingly point out that 
the clinical factors associated with the risk of severe hypoglycemia correlated with 
higher levels of FoH and FoH tended to be higher in women versus men, single versus 
married, and in individuals with depression, anxiety, and neurosis. The author identified 
that psychiatric symptoms and FoH have a bidirectional association as FoH can 
contribute to the psychiatric symptoms and, conversely, psychiatric symptoms can 
contribute to FoH. One particular study cited by the author determined that spouses and 
partners of individuals who experience severe hypoglycemia exhibit not only a FoH, but 
also experience sleep disturbances and marital conflicts. An individual case study was 
referenced illustrating an increase in the FoH after a severe hypoglycemic event thus 
resulting in a rapid deterioration in glycemic control due to the patient’s intentional 
attempts to avoid additional hypoglycemia. Additional studies cited by Gonder-
Frederick demonstrated that in one survey study, 19% of the population of surveyed 
Chinese diabetics on insulin therapy reported keeping their blood glucose too high in 
order to prevent hypoglycemia. Another international survey performed discovered 14% 
of the surveyed insulin requiring diabetics reportedly kept their blood glucose elevated 
at bedtime to prevent nocturnal hypoglycemia. An additional survey study of over 300 
Canadians with diabetes that found a large majority of patients modified insulin dosing, 
refused to adjust insulin dosages upon recommendation, or consumed more food to 
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prevent hypoglycemia due to FoH. This unwanted FoH was also said to limit 
engagement in physical activity thus negating this strategy for risk reduction.  
Gonder-Frederick (2013) identified the commonality of physical and 
psychological burdens from hypoglycemia leading to the development of FoH. A myriad 
of manifestations were attributed to FoH including: reduction in energy, helplessness, 
anger, anxiety, depression, affective disorder, panic attacks, social isolation, treatment 
dissatisfaction, poor motivation for treatment adherence, poor sleep, and poor quality of 
life.   Moreover, HCPs are more attentive to the minimization of hyperglycemia but do 
not address hypoglycemia routinely.  Patients are not inclined to address hypoglycemia 
with providers due to stigmatization and fear of imposed restriction of privileges 
(Gonder-Frederick, 2013). Although the SR required cross-referencing to better 
guarantee reliability, it was highly valid and applicable to the phenomenon of interest.  
Reach, Zerrouki, Leclercq, and d’Ivernois (2005) contributed research regarding 
the phenomenon of interest in their correlational study in one setting evaluating 28 
participants with an elevated HbgA1C >8.5% for over 6 months. The aim of the 
investigation was to analyze the absence of adjustment of insulin doses in Type 1 diabetic 
patients with poorly controlled diabetes. Therapeutic education, health beliefs, FoH, and 
motivation were major variables and questionnaires evaluating cognitive and behavioral 
items in conjunction with objective data from glucose logs were evaluated. Data analysis 
was performed using E correlation coefficient of Spearman. The findings of the study 
demonstrated patients reported: adjusting insulin when they actually did not, not 
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adjusting insulin when they actually did, and experiencing time constraints which 
influenced decision making. The study also showed that patients: did not adjust insulin 
due to FoH or weight gain, held beliefs that contextually influenced decision making, 
expressed belief without action, did not express belief but demonstrated action, and 
demonstrated actions that were not based on reasoning. The theoretical foundation for 
the study, Causal Theory of Action, strengthened the study, but the small sample size, 
limited setting, and lack of cultural diversity were perceived as weaknesses. The validity 
of the study was adequate and findings were supported by statistical evidence, but the 
reliability must be interpreted with caution. It is applicable to the problem of FoH as it 
contributes to the exploration of the influence of FoH on behavioral management. This 
study offered the conclusion that patients claim and think in opposition to their actions. 
HCPS must realize this important factor when addressing the underreported problem of 
FoH.  
Erol and Enc (2011) interjected research from a descriptive correlational study of 
345 diabetic patients in two outpatient clinics in Istanbul. Hypoglycemia, FoH, and self-
efficacy were noted to be major variables. Measurements of management behaviors, 
including avoidance of hypoglycemia and its negative consequences and the perceived 
ability to perform work tasks, were evaluated. Data was analyzed using Mann-Whitney 
U and Kruskal-Wallis with Spearman’s correlation. The findings of the study revealed 
that FoH was affected by: age, gender, marital status, occupation, classification of 
diabetes, insulin usage, treatment with oral agents, and the presence of chronic 
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complications. It also indicated self-efficacy involved multiple social factors and patient 
education improved self-efficacy scores. The descriptive study was not able to establish 
causality and generalizability was limited due to self-reported patient data. The study 
did evaluate patient perceptions and cultural components of care. The validity of the 
study was sound and it supported existing evidence that education improves FoH, but 
the data must be interpreted with caution as reliability is less than optimal.  
Anderbro et al. (2014) released a study with the objective of examining the 
association between FoH in adults with Type 1 diabetes with demographic, 
psychological, and disease specific clinical factors and differences in subgroups 
categorized by level of FoH and risk of severe hypoglycemia. Questionnaires were sent to 
764 patients with 469 respondents and measurements included the Hypoglycemia Fear 
Survey and other psychological measures. Variables included FoH, severe hypoglycemia, 
and psychological factors. The instrumentation for measurement was determined to be 
reliable and valid. Statistical analysis of this descriptive correlational study included 
univariate approaches, multiple stepwise linear regressions, Chi-square t tests, and 
ANOVAs. The study showed that several clinical factors including hypoglycemia history, 
self-monitoring, and nocturnal hypoglycemia, were significantly associated with FoH 
and were made worse with underlying anxiety. Subgroups demonstrated significant 
differences when categorized by level of FoH and severe hypoglycemia risk. The study 
concluded that there is a strong link between FoH and non-diabetes related anxiety and 
the complexity of FoH and differences in psychological and clinical variables have 
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implications for clinical practice. The study was felt to have high validity and 
applicability to the phenomena of interest, but no causal conclusions could be drawn and 
the source of the bidirectional association between FoH and anxiety could not be 
determined. The reliability of the study was limited due to methodological limitations, 
sampling issues with patients in the study considered to be low risk for severe 
hypoglycemia, and the fact that definitions and measures of hypoglycemia may not have 
captured all of the aspects of hypoglycemia risk that contribute to the FoH. The results 
did suggest that a variety of interventions are needed to approach the complex 
interactions that exist between FoH, well-being, management, and diabetic control.   
 Interventions for FoH.  There is no dispute that the FoH is a complex entity that 
represents only one variable in the prevention of hypoglycemia and the management of 
hyperglycemia. It was been previously stated in the evidence that experiencing 
hypoglycemia often triggers a fear of hypoglycemia. The FoH triggers a cyclical pattern of 
events in insulin requiring diabetics where the rational thought used for decision making 
is clouded resulting in undesired results. An unrecognized event or pattern of 
hypoglycemia can leave an insulin requiring diabetic with a sense of foreboding and 
trepidation regarding the use of insulin therapy. It is a logical hypothesis that 
empowerment of the patient with the education needed to address the prevention of 
hypoglycemia will lead to reduction in FoH and ultimately allow patients and providers 
alike the ability to more effectively manage both hypoglycemia and hyperglycemia.  
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Strategies to address the incidence of hypoglycemia and the FoH include medical, 
surgical, educational, and behavioral interventions (Gonder-Frederick, 2013). Patient 
education has long been recognized as an accepted and established method in the 
management of chronic disease. The economic and clinical benefits of educational 
interventions have been shown to positively influence patients for a minimum of at least 
twelve months following the intervention (Dalal, Robinson, & Sullivan, 2014). This is 
largely because the daily management of most chronic diseases is done by the patients 
themselves. Attempting to change patients’ perception and modify their behavior using 
an autonomy supportive approach and shared decision making is no small undertaking. 
It is vital to identify patients with FoH as a significant clinical problem and to then 
provide the underpinnings for behavioral changes. Interventions involving patient 
education should not be entirely focused on saturating patients with knowledge; it 
should involve targeting the patient’s beliefs and attitudes toward their self-management 
capabilities. Knowledge transfer is not the only answer to reducing risk. The transfer of 
knowledge must be accompanied by the support of the provider to the patient as to how 
to autonomously utilize knowledge for individual circumstances (Kubiak, Hermanns, 
Schreckling, Kulzer, & Haak, 2006).  
Advanced practice nursing involves the ability to effectively engage in teaching 
and coaching strategies geared toward optimizing individual and population health. 
Provided patient education is less effective when motivational strategies are not 
included. Autonomy supportive patient education entails acknowledgement of the 
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patient’s individualized situation and autonomous choice. Advanced Practice Nurses 
(APNs) are obligated to establish therapeutic nurse/patient relationships that consider 
patient perceptions, facilitate alternative choices, and allow patients to responsibly 
engage in the natural process of self-discovery. This also involves setting limits that do 
not compromise the legitimacy or honesty of the relationship (Johnson, 2007).  
Pedagogical interventions with a psychoeducational foundation using autonomy 
support as a foundation can promote patient motivation and patient confidence in self- 
management skills. Autonomy support is indicative of the extent to which providers 
actively listen, provide support and education, and minimize external control (Williams, 
McGregor, King, Nelson and Glasgow, 2005). This was specifically illustrated by 
Williams, McGregor, Zeldman, Freedman, and Deci (2004) in a longitudinal study. The 
study tested a process model of health behavior change for glycemic control within a 
randomized trial. Patient activation versus passive education based on the educational 
Self-Determination Theory was evaluated. One hundred and fifty nine out of 232 patients 
from a university affiliated community hospital were selected for evaluation based on 
eligibility criteria. HbgA1C, autonomous motivation and perceived confidence were 
assessed at baseline, 6 month and 12 month intervals. The Modified Health Care Climate 
Questionnaire, the Treatment Self-Regulation Questionnaire, The Perceived Competence 
for Diabetes Scale, and a Summary of Diabetes Self-Care Activities, along with HbgA1C, 
were evaluated during the study. Participants were subject to activation or passive 
education from a multidisciplinary standpoint. This study concluded that autonomous 
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motivation and change in perceived competence were found to predict improvement in 
glycemic control over a twelve month period and indirectly improved HbgA1C. A direct 
relationship between HbgA1C lowering from autonomy supportive measures could not 
be concluded, but the information discovered supported interventions that promoted 
patient’s autonomy in chronic disease self-management. It also validated prior research 
that has demonstrated that self-management education improves glycemic control and 
patients who experience autonomous motivation are more competent to attain relevant 
outcomes.  
Schachinger et al. (2005) reintroduced the concept of Blood Glucose Awareness 
Training (BGAT) in the diabetes literature. BGAT is a psychoeducational program for 
patients with Type 1 diabetes that focuses on improving the recognition and 
management of extreme blood glucose levels and is the best documented American 
psychoeducational program for this intent. BGAT is typically an 8 week outpatient 
program in a group format that: teaches patients to identify internal cues of glucose 
fluctuations, anticipate fluctuations, apply personally relevant data and engage in 
strategic homework assignments. There have been three versions of BGAT to date and 
the efficacy of BGAT has been well documented in the United States. However, initial 
European studies found that it reduced glycemic fluctuations but did not improve 
hypoglycemia detection thus raising generalizability and cultural issues. Therefore, a 
randomized controlled prospective study of BGAT III in European settings was 
performed. The RCT hypothesized that: BGAT III would lead to improved blood glucose 
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estimation, a reduction in the frequency of extreme blood glucose levels, decrease the 
frequency of severe hypoglycemia, and improve psychological functioning in terms of an 
improved internal locus of control and a reduction in FoH. BGATs effects on 
psychological variables were also examined.  
Six settings in Switzerland and Germany participated in the multicenter study. 
Approximately 400 patients were made aware of the availability of the study. Exclusion 
criteria were uncontrolled physical and mental diseases. Somatic comorbidity was 
assessed prior to the study. Six patients were excluded due to this criteria. Substance 
dependency was also assessed by self-reported data. Inclusion criteria were: intensified 
insulin regimen, three to five glucose measurements daily, recent insulin adjustment and 
dosing schedule, and routine quarterly HbgA1C evaluation. A total of 138 participants 
were randomly assigned to receive either BGAT or participate in a physician guided self-
help group. Subjects in each group were matched. Fourteen patients were excluded as 
they did not complete the training. Thirteen subjects were noted to be noncompliant and 
excluded from the study. Exclusion rates between groups were comparable. The 
intervention with BGAT focused on: internal cues, disruptions in cognitive and motor 
performance, mood changes, food consumption, insulin injections, and exercise.  
Personal data was reviewed in week eight. The self-help group guided by the physician 
allowed participants to determine the topics and no homework was assigned.  
Dependent variables included blood glucose monitoring results, number of times 
SBGM per day, and self-reports of hypoglycemia. The Blood Glucose Accuracy Index, 
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standardized questionnaires assessing locus of control and quality of life were utilized 
with each known to have proven validity and reliability. The Well Being Questionnaire, 
Diabetes Quality of Life Questionnaire, a nineteen item mood questionnaire, and the 
Hypoglycemia Fear Survey were utilized. ANOVA was used to examine the impact of the 
intervention. The primary statistic of concern was a significant interaction term. A priori 
constructed contrasts for comparison between intervals and severe hypoglycemia in the 
previous two years as a covariate in the model did not have a significant effect on the 
results, so to preserve the statistical power, the covariate was not used. All tests were 
two tailed.  
There was a marginal tendency for a higher rate of hypoglycemia in the previous 
two years in the BGAT group and other variables were comparable. BGAT led to a 
decrease in severe hypoglycemic events and increased recognition of both hyperglycemia 
and hypoglycemia. Extreme fluctuations and HbgA1C were not affected. Internal locus of 
control and unpredictability in glycemia improved. Worry and fear were also reduced in 
the BGAT group. These results are supportive of the findings from the American studies. 
BGAT has been shown to: reduce adverse clinical events without compromising 
metabolic control, improve recognition of high and low glucose, reduce external locus of 
control and reduce FoH. The positive effects of BGAT were also noted to have a long 
lasting effect on the participants. 
The limitations of the study included the possibility that BGAT participants had 
attention from two group leaders instead of one physician. Treatments were not of equal 
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length and control participants did not participate in homework. Control group 
participants were not obliged to talk about hypoglycemia. Blinding was not possible due 
to the delivery of behavioral treatments. Behavioral treatments may also have been 
influenced by cultural factors.  
Wild et al. (2007) proposed that BGAT, specific training designed to improve 
awareness of blood glucose symptoms and factors leading to glycemic variability, may 
reduce both the IoH and the FoH. This is, in turn, anticipated to improve the quality of 
life and patient safety in insulin requiring diabetics. A study by Weinger and Jacobson 
(2001) as cited by Wild et al. (2007) found that BGAT may be effective for reducing the 
FoH and increasing appropriate diabetes management behavior. Gonder-Frederick 
(2013) summarizes BGAT in the SR of the literature by citing the works of Cox et al. 
(2001) and Schachinger et al. (2005) with their work with BGAT focusing on the 
improvement of the patient’s ability to accurately recognize symptoms of hypoglycemia 
and better predict glycemic patterns. BGAT improved detection of hypoglycemia, 
reduced the frequency of severe hypoglycemia, and reduced FoH.  
There is direct applicability of BGAT to the clinical question as it addressed the 
frequency and fear of hypoglycemia. BGAT’s reproducibility in a real world practice 
setting is a major barrier and thus, the intervention requires a translational approach. 
The adaptation of BGAT to delivery in a real world setting can be achieved by extracting 
the specific components of BGAT that are directly related to hypoglycemic prevention, 
recognition, and treatment in a self-study module with assigned homework and 
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individualized instruction. The entire BGAT program need not be reproduced to reap the 
benefits of its inception. A real world practical educational intervention is anticipated to 
achieve positive results while preserving the spirit of BGAT.   
The real world of clinical practice often presents financial, time, and patient 
imposed barriers. Intervention strategies based on a sense of realism are more apt to be 
implemented than complex idealistic approaches. Translational research occurs in two 
continuous phases: from bench to bedside and from clinical research settings to real 
world practice. It is not acceptable to investigate relationships between factors and 
outcomes in a research setting without testing interventions and documenting outcomes 
in real world settings. Intervention research is desperately needed and is one of the 
highest priorities in diabetes translational research (Garfield et al., 2003).   
Limitations 
 There are definitive limitations to the review of the relevant literature. The major 
limitation perceived is the lack of a standardized definition of hypoglycemia and FoH in 
the literature. Hypoglycemia cannot simply be defined by a numeric value; it must also be 
conceptualized as the degree of glycemia that is noted to induce behavioral, cognitive, or 
motor disruptions in a diabetic individual. The FoH phenomenon has not been 
specifically defined and its variables have not been explicitly stated. There is a lack of 
strong empirical evidence as to how the FoH impacts on long term outcomes. There is a 
considerable lack of data defining strategies to increase awareness among health care 
providers. The topic of hypoglycemia and its impact on diabetes management is sadly 
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unrecognized and considered secondary to hyperglycemia. Poor metric collection 
strategies do not allow for the light to shine on this clinically important aspect of 
diabetes care. The lack of causality when discussing the phenomenon of interest clearly 
indicates the need for more research to be done on both an observational and 
interventional front. There is a lack of data involving culturally diverse diabetic patients 
as well as a lack of attention to practical strategies that may be employed to address this 
common, yet complex, clinical dilemma. The BGAT strategy has been applied to Type 1 
diabetics; however, severely insulin deficient Type 2 diabetics demonstrate many of the 
same physiological problems as their Type 1 counterparts and data supporting BGAT in 
insulin requiring Type 2 diabetics is required. There is also currently no guidance for 
health care providers regarding how to utilize the limited available data in clinical 
practice (Ryan, 2013).  
Conclusions 
 The incidence of diabetes is anticipated to increase over the next few decades at a 
time when the allocation of resources is dwindling. This rise in the incidence of diabetes 
and its complications is surely to have a significant clinical impact on the health and 
well-being of the population of the United States. The progressive nature of diabetes 
often necessitates the use of insulin therapy as a life preserving and life sustaining 
treatment. The need for insulin is absolute, but with this therapy comes an increased risk 
of iatrogenic hypoglycemia. Hypoglycemia is the greatest barrier to the achievement of 
good glycemic control and stands in the way of proper hyperglycemia treatment. The 
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unrecognized and unaddressed complication of iatrogenic hypoglycemia causes 
significant physical, psychosocial, and financial ramifications. Hypoglycemia that is left 
untreated begets more hypoglycemia. This cyclical process allows for the development of 
the FoH. This fear can trigger maladaptive coping strategies that interfere with diabetes 
management and serve as additional risk factor for poor long term outcomes. The 
prevention, recognition, and treatment of hypoglycemia and its associated psychological 
consequences needs to be a priority when addressing the care of the diabetic patient. 
Diabetes is a vastly self-managed disease requiring the application of learned knowledge 
and the support of health care providers through autonomy support. Education is a key 
to self-management, empowerment, and self-efficacy. Education specialized to the topic 
of hypoglycemia can reduce the incidence and fear of hypoglycemia. It is anticipated that 
these reductions will improve quality of life and reduce risk. The time for translational 
research in diabetes to address issues such as hypoglycemia and the fear it generates is 
now.   
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Chapter 3: Conceptual Model for Evidence Based Practice Change 
 The only constant in healthcare is that it is dynamic. Scientific evidence may 
sometimes be considered absolute, but the manner in which it is applied and how it is 
transformed into new evidence is an evolutionary process. Transformation of evidence is 
required to stay on par with the needs of the population in new eras and changing 
environments. A multidimensional approach is mandatory to address the transformation 
of healthcare. Evidence based practice is one of the dimensions that demands clinician 
attention.  (Stevens, 2006).  Evidence based practice is a problem solving approach to 
clinical decision making that couples the soundest research evidence with the best 
available clinical expertise to form a criterion to measure care and achieve more 
consistent patient outcomes (Hickey and Brosnan, 2012). It is frequently not a lack of 
evidentiary knowledge nor the desire for implementing a practice change that stalls 
clinicians; it is the manner of how to take the evidence and translate it into a useable 
format in a real world setting. Translating evidence into practice is explicated by the use 
of a conceptual model for evidence based practice change.  
Conceptual Definitions 
 The definition and purpose of a conceptual model.  A model, or conceptual 
framework, is a set of concepts and assumptions that are arranged into a useful 
configuration in order to describe the relationships that exists between them (Mensik, 
Martin, Scott, and Horton, 2011).  It is imperative that concepts are defined for the 
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purposes of accurate communication. Models must be identified within research to 
contextually illustrate how information is interpreted for clinical decision making.  
Models assist clinicians in the organization of thoughts regarding evidence based 
practice, guide design and implementation strategies, and strengthen decision making 
skills (Stevens, 2013). They steer evidence based practice changes to prevent deficiencies 
in program implementation and guarantee that time and resources are used to their 
greatest value. Models aid in moving evidence to practice by focusing efforts and 
providing a systematic approach to evaluation of the evidence thus resulting in the 
optimization of patient outcomes despite being less rigorously tested in comparison to 
theories (Gawlinski and Rutledge, 2008). 
Choosing an appropriate model entails the consideration of: clarity, organization, 
comprehensiveness, ease of use, practicality, and versatility. Most models have 
commonalities, however, contextual differences may make some models more applicable 
to a situation than others (Gawinski and Rutledge, 2008). The implementation of a 
model requires the consideration of multiple factors. Patient preferences, clinical states, 
settings, contextual circumstances, and the availability of healthcare resources are used 
to weigh the decision. The quality of research evidence, available clinical expertise, and 
the amalgamation of the two, are also factored into the decision making process. The 
development of guidelines helps to focus on improvement strategies that are useful in 
real life settings when attempting to change practices (Melnyk and Fineout-Overholt, 
2015).   
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The ACE Star Model of Knowledge Transformation. 
 Overview.  Evidence based practice changes can occur with the transformation 
of knowledge. This involves the conversion of singular studies that are cumulatively 
evaluated for their impact on health outcomes. This transformation is necessitated before 
research can be useful in decision making. The translation of scientific evidence occurs 
within the context of clinical expertise and other information resulting in practice 
recommendations. These practice recommendations need attention at individual, 
organizational, and environmental levels (Stevens, 2006). Clinicians are hindered in 
making evidence based practice changes by the obstacles of complexity, volume of 
information, and the numerous forms in which the available evidence is bundled. These 
obstacles need to be overcome by the development of evidence summaries and the 
transformation of knowledge through systematic steps to increase their meaning and 
utility in real world practice (Stevens, 2004).  
The goal of the ACE Star Model is to convert research findings through a series of 
steps in order to use evidence to impact upon health by using knowledge types as 
precursors to practice integration. (Gawlinski and Rutledge, 2008). The ACE Star Model 
explains how to cope with the volume of evidence, the inability to link the form of 
knowledge in its current state to a clinical situation, and the integration of expertise and 
patient preferences. Despite the fact that not all knowledge can be translated into 
clinical practice, this model makes an impact on health by way of evidence based action 
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and organization of key points to provide a basis for quality improvement initiatives in 
preparation for more advanced models (Melnyk and Fineout-Overholt, 2015). It builds 
upon the basic nursing process, yet places an emphasis on evidence based care. The 
model’s simplicity is evident in the way it illustrates a sequential move from one step of 
transformation to the next allowing for the synthesis of amassed evidence to be funneled 
into a practical recommendation (Gawlinski and Rutledge, 2008), but it is 
comprehensive as it encompasses new knowledge for practice integration (Stevens, 
2004).  
 Assumptions.  The ACE Star Model identifies eight assumptions (Appendix D) 
which are detailed in this section. The first assumption is that knowledge transformation 
is necessary before it can be used in clinical decision making. The second assumption is 
that knowledge is obtained from multiple sources. The third assumption states that 
generalizable knowledge is discovered through the research process. The fourth 
assumption indicates that evidence is hierarchically categorized according to the 
strength of the evidence as determined by rigor. The fifth assumption states that 
knowledge is found in different forms. The sixth assumption identifies that knowledge is 
relative to its contextual use. The seventh assumption asserts that the form of the 
knowledge determines its utility. Finally, the eighth assumption avows that knowledge 
is transformed by the steps of summarization, translation, integration, and evaluation 
(Stevens, 2004).  
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 Model and stages.  The ACE Star Model is visually depicted as a five point star 
with each point of the star representative of a stage of knowledge transformation needed 
for evidence based practice change (Appendix E).  Stevens (2004) described the 
schematic of the visual representation. The first point of the star represents the stage of 
discovery. This stage is considered the knowledge-generating stage and serves as the 
foundation for clinical action. The second point represents the evidence summary stage. 
This stage is known to include the synthesis of research into a singular statement 
regarding the phenomena of interest that continues knowledge generation by 
accumulating the most rigorously evaluated evidence through critical appraisal. This 
stage entails: the management of data, the generalizability of data, determination of the 
consistency of the data, identifying cause and effect within the data, reducing bias, 
synergy of old and new data, and the efficiency of the data. This second stage is 
considered ground zero for future evidence updates. The third point depicts the 
packaging of translated evidence. This is typically in the form of care standards, 
pathways, protocols, or algorithms used in clinical decision making. This is the stage 
where clinical research is combined with theoretical guides and clinical expertise for 
conceptualization to a specific population or setting to articulate the link between the 
recommendation and the evidence. The fourth point of the model represents practice 
integration. It is in this stage that change by the individual or organization through 
formal and informal channels is accomplished depending upon the rate of adoption of the 
change. Lastly, the fifth point symbolizes process outcome and evaluation. This is where 
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endpoints and outcomes are evaluated for the determination of impact on health 
outcomes, satisfaction, health status and efficacy. Efficacy notably includes ease of use 
and cost analysis.  
Relationship of Model to the Project 
 The ACE Star model was applicable to the EBP and provided a very efficient 
template to pave the way for evidence based changes. The EBP required the research to 
be translated into a useable form for application in a real world setting to improve 
quality and patient satisfaction, as well as to enhance patient safety. It was also the 
intent of the researcher that this EBP would stimulate additional scholarly inquiry 
regarding ways to address the phenomena of hypoglycemia for incorporation into project 
investigator’s (PIs) electronic medical record for use throughout an individual 
organization.  
 The first stage of knowledge translation was the identification of the clinical 
problem – the barrier of hypoglycemia on diabetes management.  The project focused 
attention on FoH as the primary topic in diabetes management, the FoH. This stage 
called for the PI to collect evidence in the form of descriptive and correlational studies, as 
well as randomized controlled trials, to establish a data base of evidence. The PI 
discovered that BGAT was an effective approach in the reduction of FoH and improved 
patients self-management skills.  
The second stage of knowledge translation continued the generation of 
knowledge through PI’s evaluation of SRs and other relevant literature. The available 
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evidence was able to be narrowed in this stage. Evidence demonstrated that education 
positively impacts upon the phenomenon of hypoglycemia and reduces the FoH despite 
the fact that additional research is required to demonstrate an impact on long term 
health outcomes and prevention of complications. The FH-15 Scale determining FoH was 
ascertained to be a valuable tool in data collection regarding FoH pre and post 
intervention. The obstacle connected with BGAT was its limited feasibility in its current 
state for use in a busy individual practice setting with limited resources and available 
providers. BGAT required the selective extrapolation of specific components for the 
successful implementation in a real world clinical practice.   
The third stage of knowledge translation was to evaluate the current clinical 
practice guidelines available for the prevention, detection, and treatment of 
hypoglycemia to impact upon FoH and IoH in insulin requiring adult patients. The 
evidence based guidelines articulated the link between the prevention of hypoglycemia 
and the development of FoH as a limiting factor to achieving adequate glycemic control. 
The packaging of relevant data in a single entity was more useful to the PI in determining 
how to apply the standards of care.  
The fourth stage of the project involved the selection of one component of BGAT 
for implementation as BGAT in its original form was noted to be typically beyond the 
implementation of individual practices in a real world setting. The selected educational 
component dealing with the phenomenon of interest, hypoglycemia, was targeted for 
additional evaluation to determine the impact upon FoH and IoH. The EBP intervention 
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involved planning by the PI within an individual practice setting and collecting data 
regarding its efficacy. 
The final stage of knowledge transformation included the evaluation of the EBP’s 
endpoints and outcomes regarding FoH and IoH. Evidence regarding outcomes was 
compiled for dissemination to the organizational board of physicians and packaged for 
presentation to the policy and procedure group of the organization for incorporation into 
the electronic medical record for use in all individual sites caring for insulin requiring 
adult patients. Collaboration with information technology specialists within the 
organization for determination of methods for metric collection regarding the 
phenomenon of hypoglycemia is anticipated to be forthcoming. The widespread 
implementation of hypoglycemia education across the organization will improve quality, 
increase patient satisfaction, and safeguard the health and well-being of patients with 
insulin requiring diabetes.  
Conclusion  
The move to expand the use of evidence based approaches in clinical practice is 
crucial for the transformation of healthcare. The amount of information available and the 
form in which this information exists is not always conducive for translation into real 
world practice.  The utilization of a conceptual model to organize the development of a 
project cannot be understated. The use of a logical framework by the clinician to 
undertake the task of clinical inquiry simplifies the process into measureable steps. The 
ACE Star Model for Knowledge Transformation is one model that is illustrative of how a 
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simplistic framework can incorporate complex ideologies and guide clinical inquiry for 
the purpose of quality improvement.  
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Chapter Four: Project Design 
Project Design 
 Clinical research can either generate new evidence upon which practice should 
be based or it can evaluate the applicability and effectiveness of research findings for use 
in clinical practice on populations of interest. EBPs use a translational approach to 
research to bring about change in practice for the purpose of improving patient 
outcomes. Scrupulous attention to methodology that supports the project is a necessity 
for the project to be useful and ethical. Reliability of the project requires adherence to an 
evidence based process to ensure the project does not violate the principle of justice 
through the wasting of limited resources or violate the principle of beneficence through 
the result of ineffective outcomes (Melnyk and Fineout-Overholt, 2015). The purpose of 
this chapter is discuss the planning process for the EBP.  
 Project Purpose. The purpose of the project was to evaluate the effectiveness of 
implemented standard of care best practices, specifically an evidence based, 
psychoeducational tool extrapolated from BGAT, on FoH and IoH in insulin requiring 
adult diabetics.  The reasons for the conceptualization of the EBP were two-fold: FoH is 
a major deterrent in the achievement of the degree of glycemic control required to 
prevent long term diabetic complications and insulin associated ADEs can significantly 
jeopardize patients’ safety and psycho-social well-being. Scholarly inquiry and an 
extensive literature review regarding the topic of interest demonstrated that BGAT was 
an effective intervention for the reduction of FoH. However, BGAT was not deemed 
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practical for the purposes of the practice or the organization due to recognized barriers 
to implementation. Thusly, the prior evidence based implementation required a 
translational approach for adaptation to real life practice and subsequent evaluation to 
ensure its applicability and beneficence.  
 Project Management.  An assessment of the feasibility in which an EBP is to be 
conducted must be performed prior to the implementation of change. Additionally, 
establishment of a thorough plan of action in preparation of the project must be 
considered during project planning. This EBP included: an organizational assessment, 
information technology assessment, Institutional Review Board (IRB) approval, data 
collection planning, and resource allocation planning.  
 Organizational topics. An organizational assessment included evaluation of the 
need for practice change, availability of collaboration, evaluation of potential barriers and 
a strategy in which to mitigate the identified barriers (Moran. Burson, and Conrad, 
2014). The need for practice change was identified by the existing members of a single 
healthcare system owned Endocrinology practice. The existing members of the practice 
consisted of one board certified Endocrinologist, one Certified Registered Nurse 
Practitioner (CRNP), and one Certified Physician Assistant (PA-C). Consensus was 
achieved among the practice providers that there was an ongoing need to supportively 
educate patients on the recognition, prevention, and appropriate treatment of 
hypoglycemia. Interprofessional collaboration was utilized for the purposes of securing 
differing perspectives on the topic of interest. It was agreed that implementation of the 
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EBP would be initiated in the individual practice site with the potential for the results to 
be disseminated throughout the organization. It was theorized that successful 
implementation of the EBP could result in future widespread implementation and data 
collection used to improve the health of the identified population. Consultation with 
nursing and patient care staff was initiated by the CRNP to obtain other professional 
inputs to determine project worthiness. The individual practice site was deemed 
appropriate due to a desire to stimulate evidence based practice changes for the purpose 
of improving patient outcomes. Supporting organizational characteristics included: a 
high percentage of insulin requiring adult diabetic patients managed by the CRNP and 
the availability of resources to enact the practice change. Organizational approval to 
institute the project was granted by both the practice manager and the office manager. It 
was determined that all insulin requiring adult diabetics evaluated by the CRNP in a 
single practice site would be provided the availability of the same accepted evidence 
based practice guidelines for diabetes management. A survey measuring FoH and IoH 
was administered prior to the intervention and four weeks post intervention on 
participating patients for comparison. Informed consent (Appendix F) was obtained 
prior to patient participation to uphold ethical standards. The intended outcomes of the 
EBP intervention were to: reduce the FoH and IoH.  
 An analysis of the project using a strengths, challenges, opportunities, and threats 
(SCOT) analysis as defined by Melnyk and Fineout-Overholt (2015) was performed. The 
strengths of the project included the clinical need for practice change, organizational 
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support within the practice, and patient acceptance of receiving information. The 
challenges identified included: time management, securing patient enrollment, resource 
allocation and patient health literacy. Additionally, neither the practice nor the 
organization has a department dedicated to organizational research. The opportunities 
provided by the project included improved communication with patients, improvement 
in patient outcomes, and the ability for disseminated information retrieved from the 
project to stimulate an organizational change for improving population health and data 
collection for future research. The project also encouraged adherence to evidence based 
practice standards from the ADA (2015) and The Endocrine Society (2009) through the 
provision of ongoing provider supported patient education regarding diabetes self-
management.  Threats to the project were perceived to be time management, patient 
participation, and the future acceptance of disseminated information by the organization 
for stimulating changes in practice on a more widespread scale. These threats were 
mitigated by: modification of recruitment time for the project, ongoing preparation for 
impromptu meetings due to time constraints, adherence to informed consent, utilization 
of an LPN liaison, discussion of the project with the a physician member of the Board of 
Directors, and formation of a relationship with an IT and QI supervisor to incorporate 
education in the EMR.    
 Use of Information Technology.  The utilization of IT in healthcare has become 
increasingly important in improving quality of care, supporting decision making, 
documenting adherence to standards of care, and improving patient safety. The EMR 
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serves as a tool to address each of these factors. The practice in which the intervention 
took place utilized an EMR and the password protected Centricity electronic database. 
The pedagogical tool utilized in the project was researched utilizing multiple databases 
accessed on the internet and was developed using Microsoft Word. Data collection was 
accrued in the EMR for retrospective evaluation of outcomes from implementation of 
best practice in diabetes management. Data analysis was performed using Microsoft 
programs. IT methods for dissemination of project results regarding diabetes 
management was done using the Microsoft Word and Power Point programs.    
 Institutional Review Board Approval.  IRBs have been established for the 
purpose of reviewing and monitoring research involving the participation of human 
subjects to ensure the protection of their rights and welfare (United States Food and 
Drug Administration, 2014). The PI completed certification from the National Institute 
of Health on protection of human subjects in research in accordance with IRB policies 
prior to the project launch (Appendix G).  
Interestingly, at the initiation of project planning, the organization in which the 
project took place did not have an established IRB; however, the parent healthcare 
system which owns the organization was noted to have an IRB. Organizational IRB 
requirements were investigated and preparation for review was done. One week prior to 
the submission of project information to the organization’s IRB, it was discovered that 
the committee had been dissolved due to lack of participant interest and resignation of 
the IRB physician chair. Therefore, organizational IRB approval was not able to be 
71 
 
 
 
  
 
sought nor obtained. Project information was submitted to the Misericordia University’s 
IRB in Dallas, Pennsylvania and the project was approved in May 2015 (Appendix H).  
Data Collection Tools 
 The quality of a measuring tool that was used in data collection for translational 
research was based upon the instrument’s reliability and validity. Reliability estimates 
measurement stability and internal consistency, whereas validity focuses on the extent 
to which interpretation of the results are warranted. Translational research in healthcare 
may also require the collection of data via self-reporting by patients but must be 
interpreted with caution due to the risk of bias (Kimberlin and Winterstein, 2008). This 
project used both an instrument for data collection in addition to self-reported data with 
each having distinct differences in reliability and validity but determined to be useful 
nonetheless in translational research.  
 FH-15.  The FH-15 Scale was used in the EBP for practice improvement. 
Permission for use of the FH-15 Scale was granted by Professor Maria Teresa Anarte-
Ortiz from the Department of Personality, Assessment, & Psychological Treatment 
Faculty of Psychology at the University of Malaga in Spain. This scale was determined to 
be applicable to the selected clinical problem and population as it provided an adequate 
instrument to specifically measure FoH and was directly linked to clinical inquiry. Its 
advantages were determined to be: use as a rapid assessment tool in determining 
hypoglycemia, assistance in the development of a patient centered individualized 
treatment plan for the prevention of ADEs, and improvement in the use of medical 
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resources for successful patient outcomes by addressing factors that contribute to 
treatment noncompliance. The scale was tested in a cohort study using the methodology 
of Factor Analysis with a principle components method and involved 229 voluntary 
participants recruited by a clinical psychologist in a diabetes unit in an endocrinology 
department. The study collected socio-demographic data and evaluated the subjective 
perception of FoH. Rigorous data analysis was performed concluding that the FH-15 
scale had good test/re-test reliability with good sensitivity (0.736) and specificity (0.807) 
with a positive predictive value of 0.779 and a negative predictive value of 0.768. It was 
concluded that the instrument alone cannot comprehensively evaluate the complex 
phenomenon of FoH and requires additional research in various diabetic cohorts. 
However, it specifically measures FoH, has the potential for widespread use, and was 
useful in clinical practice as it demonstrated efficient use of time and helped to identify 
patients at risk that may require more intensive psychological intervention (Anarte-
Ortiz, Caballero, Ruiz de Adana, Rondan,, Carreira, Dominguez-Lopez, … and Soriguer, 
2011).  
 Demographic data collection included: ethnicity, gender, age, the use of insulin as 
monotherapy, and the presence of a significant other residing in the home.  Additionally, 
the number of estimated incidents of hypoglycemia in the past four weeks was self-
reported by the patient participants at baseline and four weeks post intervention. All 
data collected for the project were normally collected as part of standard of care for all 
insulin requiring patients in the practice evaluated by the CRNP.   
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Data Management 
Information associated with the project was confidentially maintained on the 
password protected Centricity electronic database that was accessible only to the PI. 
Patient participants who agreed to receive the informational tool and in which informed 
consent was obtained were identified in the EMR upon retrospective chart review. Each 
patient was assigned a numeric code to be used in place of any identifying information in 
any and all retrospective data collection used for the EBP to protect the anonymity of the 
patient. Absolutely no patient identifiers were used in the documentation of the project 
findings or disclosed. No other information was used.  
Data Evaluation   
A non-experimental EBP for the purpose of stimulating practice change differs 
from traditional research despite overlapping characteristics (Melnyk and Fineout-
Overholt, 2015). The cross-sectional design of the project entailed the collection of 
measurements at the same point in time. The FH-15 survey data was evaluated pre and 
post intervention in addition to the self-reported estimates of the number of 
hypoglycemic events experienced within the past four weeks pre and post intervention. 
Survey data were collected in person or via phone interview. The chart review involved 
the evaluation of a convenience sample and the use of descriptive statistics to explain 
demographics. Paired two-tailed t tests were used to determine the differences between 
the two sets of data.   
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Required Resources 
 Several resources were required for the EBP.  A provided copy of the informed 
consent, printed pre and post FoH survey forms, and a copy of the written intervention 
tool was required for each voluntary participant. A laptop computer equipped with 
Centricity, copy paper, ink cartridges, pens, copy machine, and Microsoft Office 
software was deemed necessary. Facilities with an exam room were required. 
Glucometers and/or test strips were provided to patients who did not have one for home 
use. A privacy secured locked disposal system for discarded documents was marked for 
incineration and used in conjunction with other resources such as a telephone system 
and office support staff services for scanning information into the EMR.  The services of 
an LPN trained in the protection of human subjects was employed for data collection in 
the event the project manager required assistance (Appendix I). There was no cost 
associated for obtaining permission to use the FH-15 Scale. Statistician services were not 
required.    
Budget Justification 
 The EBP was considered to be low cost and affordable. The required resources 
were purchased by the practice for the quality improvement project in advance of the 
retrospective data collection. The bulk of the cost associated with the practice 
implementation was comprised of paper and ink for the printing and distribution of 
surveys and psychoeducational materials to patients accepting the interventional tool. 
The maximum amount allotted would be 100 copies of each for the period of recruitment. 
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Glucometers and test strips were earmarked for patients who did not have use of these 
items prior to retrospective data collection, were provided gratis by multiple 
pharmaceutical companies, and are routinely available in the office setting.  The 
retrospective data collection associated with the project after implementation involved 
the use of existing equipment that was included in the day to day operations of the 
practice. These items included: a laptop equipped with Centricity, copy machine, 
Microsoft Office software, privacy ensured document disposal, a telephone system, 
facilities and personnel for scanning information.  The additional allocation of financial 
resources required for the project included the employment of the LPN for assistance 
with data collection and time for training on protection of human subjects in research. 
The anticipated amount of LPN reimbursement time for the project was estimated at no 
more than $250.00.  The utilization of the LPN to ensure the success of the project in the 
event of time management issues was determined to be imperative. There was no cost for 
obtaining permission to utilize the FH-15 Scale or for statistician services.   
Conclusion  
 Undertaking an EBP for practice improvement is not necessarily a cut and dry 
process. Planning an implementation demands the creation of a step-by-step process to 
guide management, but it must also allow some flexibility as actual implementation is 
not as forthright. A well-formulated project plan ensures success and provides a better 
chance of reproducibility in the event the project is successful. Hypoglycemia is a major 
barrier to the achievement of adequate glycemic control and can wreak havoc on diabetic 
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patients and their loved ones. This EBP sought to practically incorporate 
psychoeducational information during routine follow up of diabetes care for the purpose 
of reducing FoH and IoH. It represented an initial step in practice and organizational 
change that has the potential to reduce health care costs and improve patient safety in 
accordance with national action planning.  
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Chapter 5: Project Implementation 
Preparation 
 Problem Identification and Project Justification 
 Diabetes currently afflicts millions of people and the population of individuals 
with diabetes is expected to continue to rise (ADA, 2014). The progressive nature of the 
disease and the devastating consequences from chronic hyperglycemia frequently require 
the utilization of insulin therapy to prevent the onset or progression of diabetic 
complications. Treatment with insulin therapy, although often life-sustaining, is not 
without potential risks. Iatrogenic hypoglycemia is an ADE that can trigger patients to 
experience fear associated with the same therapy that is meant to protect their health. 
FoH can serve as a major barrier to the achievement of glycemic control adequate enough 
to prevent diabetic complications (Wild, et al., 2007). Iatrogenic hypoglycemia is the 
most commonly experienced ADE associated with insulin use (HHS, 2014) and has 
physical, psychosocial, financial, and safety implications that affect individuals, families, 
communities, and populations. Ongoing education regarding the recognition, prevention, 
and treatment of hypoglycemia has been evidenced to reduce FoH and improve self-
management skills in diabetic patients (Wild, et al., 2007). National guidelines have 
suggested routinely addressing hypoglycemia in insulin requiring patients to improve 
patient safety (HHS, 2014) and experts concur that inquiry by clinicians regarding 
hypoglycemia in the insulin requiring patient should occur at every encounter. (The 
Endocrine Society, 2009).  
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 Identification of the clinical problem, accompanied by an extensive review of the 
relevant literature, was performed prior to the implementation of the EBP. Furthermore, 
the EBP was foundationally supported by linkage to the ACE Star Model of Knowledge 
Transformation. The project design was formulated with the purpose of evaluating the 
effectiveness of implemented standard of care best practices on the improvement of FoH 
and IoH in insulin requiring adult diabetics. Interprofessional collaboration, stakeholder 
involvement, organizational issues, and the use of IT were examined in project 
management. Data management and evaluation were conceptualized. IRB approval was 
sought and obtained on May 13, 2015 and valid until August 16, 2015. Instruments for 
data collection were critically appraised and required resources were defined. Compiled 
information extrapolated from BGAT was used to compose an evidence based 
pedagogical tool aimed to improve the recognition, prevention, and treatment of 
hypoglycemia. The tool included BGAT derived strategies and patient homework 
assignments.  
Incorporation of best practice standards into individualized care assists clinicians 
in the challenging task of caring for insulin requiring diabetics. Translational research 
bridges the gap from bench to bedside as it determines how best practice standards are 
applied. The EBP was planned and implemented to address the clinical problem of 
interest. The purpose of this chapter is to detail the implementation procedures and 
processes of the EBP.  
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Project Setting and Participants 
 The setting in which the EBP took place was a health care system owned 
Endocrinology practice in Luzerne County located in a region of northeastern 
Pennsylvania. Statistically, the majority of patients cared for in the practice were 
primarily insured by Blue Shield with Medicare as the second largest insurer of practice 
patients. Endocrine services within the setting were provided by a Board Certified 
Endocrinologist, a CRNP, and a PA-C. Cumulatively, an estimated 50 to 70 patients with 
a variety of endocrine disorders were evaluated in the practice on a daily basis. The EBP 
was implemented by the CRNP, otherwise known as the PI. The population selected for 
the EBP included all adult insulin requiring adult patients evaluated by the PI between 
June 2, 2015 and June 12, 2015 who met inclusion criteria.  
Implementation Procedures and Processes 
 The EBP was implemented in four distinct phases as summarized in a visual 
timeline (Appendix J).  
Phase One.  Implementation of the EBP took place daily on the aforementioned 
dates during normal office hours to ensure the implementation could be successfully 
completed during an actual patient encounter in order to be considered translatable to 
real life clinical practice. The enrollment time frame for the EBP was initially estimated 
at four weeks; however, in the interest of time and to mitigate the risk to the project, the 
CRNP’s patient encounter schedule was examined for a two week time period prior to 
implementation and considered by the PI to be sufficient for capturing patient 
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participants of an adequate number. The implementation phase of the EBP started on 
June 2, 2015 and continued through June 12, 2015. Each patient was counseled 
individually regarding hypoglycemia in accordance with the usual standard of care. Each 
patient agreeing to participate in the FH-15 survey was queried. Patients were provided 
with the created pedagogical tool extrapolated from BGAT when accepted. Each patient 
was encouraged to read the information, consider the homework assignments, and apply 
the learned information to daily management. All participants agreeing to retrospective 
data collection from their records were additionally provided with informed consent and 
a copy of the consent form. Participants were informed that a follow up phone interview 
by the PI or LPN assistant to the PI trained in the protection of human subjects would 
voluntarily occur in one month. Reiteration of the retrospective collection of de-
identified information was provided to each patient. The time commitment required per 
patient for project implementation for phase one was approximately fifteen minutes 
with slight variations required depending on patient health literacy and the need for 
repetition or additional explanation.  
Phase Two.  The time frame between June 12, 2015 and July 2, 2015 included 
education of the assistant LPN in protection of human subjects and the maintenance of 
an open line of communication between the project manager and patient participants 
regarding any issues of concern or questions that arose.  
Phase Three.  The time frame between July 2, 2015 and July 12, 2015 was utilized 
for daily follow up telephone interviews of the EBP participants. This phase involved the 
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PI or the assistant LPN conducting a post-intervention FH-15 survey with the 
participants and having each participant estimate the IoH over the past four weeks as 
noted in their glucose log or by patient recollection. It was determined patients would be 
considered voluntarily withdrawn from the EBP if post project data indicated: the 
patient did not read the provided information, was deceased, hospitalized, voluntarily 
withdrew, or was unable to be contacted after three individual attempts on three 
separate days within one week starting the first day of the four week benchmark date.  
Phase Four.  The time frame between July 12, 2015 and August 12, 2015 was 
utilized for program evaluation. The FH-15 pre- and post-intervention were compared. 
The data were entered into the secured Excel spreadsheet for data analysis. Descriptive 
data analysis and paired two-tailed t-test were used to evaluate pre- and post-
intervention data. The findings were analyzed to substantiate the original clinical 
question of “Does individualized self-management education influence the FoH and IoH 
in adult patients diagnosed with insulin requiring diabetes mellitus within 4 weeks?”  
Data Collection 
 All patient interviews were conducted individually in a private office. 
Confidentiality was maintained and no personal identifiable information was 
retrospectively collected. Each patient was linked to an identifier code number on the 
FH-15 and incidence of hypoglycemia survey. An Excel spread sheet was used to enter 
the data from survey tools and for data computation. Data were secured by the use of de-
identified code system, the use of a locked file in a private office, and electronic data 
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secured on a password protected computer. All paper data was destroyed by disposal 
into a locked professional disposal system of privacy protected documents marked for 
professional incineration. All electronic files were permanently deleted. 
Conclusion   
 Ongoing education regarding the self-management of diabetes continues to be 
the cornerstone of disease management (Erol and Enc, 2011). This EBP was intended to 
investigate a method of improving the quality of care to insulin requiring adult diabetic 
patients. Project implementation processes and procedures were clearly delineated for 
the purpose of understanding what the EBP provided and how it was provided. 
Evaluation of an EBP was required to prove usefulness in clinical practice and 
worthiness of additional inquiry and for the dissemination of information. The results of 
the EBP were intended to stimulate additional changes in order to improve patient and 
population outcomes. 
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Chapter Six: Evaluation and Outcomes 
Introduction  
A population needs assessment and a thorough review of the relevant literature 
regarding the topic of FoH demonstrated that iatrogenic hypoglycemia is the most 
commonly experienced ADE associated with insulin use and is notably one of the biggest 
barriers to the attainment of glycemic control and stability (Amiel, 2009).  The barrier of 
FoH develops through the construction of maladaptive behaviors; thus it becomes 
essential for insulin requiring patients and their HCPs to deconstruct this barrier and 
rebuild a solid foundation of knowledge in its place using a population based and patient 
centered approach to diabetes self-management. FoH is often overlooked or 
underestimated by providers and distressing to a large percentage of diabetic patients 
who must rely on insulin therapy as a life-sustaining measure for the prevention of 
diabetic complications associated with hyperglycemia (Seaquist, 2013). HHS (2014) has 
identified the need to address the risks associated with iatrogenic hypoglycemia through 
the use of multiple methodologies meant to mitigate the variables that lead to this ADE. 
Attention to hypoglycemia has been judged to be a high priority and has been included in 
HHS National Action Planning. (2014).      
This EBP was intended to add to the knowledge base of translational diabetes 
research and demonstrate how the application of best practice strategies can be 
translated into real world clinical practice for improvement of quality care and patient 
safety.  The supposition was made at the inception of the project that the practical 
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provision of self-management education derived from BGAT that addressed the topic of 
hypoglycemia in insulin requiring diabetics would influence FoH and IoH. It was hoped 
that the EBP would demonstrate an influence on the FoH and IoH in a positive manner 
in order to allow the PI to use the information gleaned from the project to:  promote 
population health, improve patient safety, stimulate additional scholarly inquiry, and 
prompt organizational change in accordance with national action planning. The project 
objectives were congruent with HHS (2014) National Action Planning and the need for 
practice changes addressing hypoglycemia supported the need for the project. The 
purpose of this chapter is to discuss the project data results and analysis, establish a 
relationship to the project framework, and demonstrate the relationship of the results to 
the project’s objectives.  
Establishment of the Project Population  
 The EBP was conducted over a ten week time period. The PI evaluated a 
cumulative total of 89 insulin requiring adult patients in the endocrinology setting 
between 9a.m. on June 2, 2015 and 4:30p.m. June 12, 2015. All patients were provided 
with hypoglycemia education in accordance with best practice standards. A total of 14 
patients were excluded from the cumulative 89 patients evaluated for potential 
enrollment in the project based on the following: 9 patients declined project 
participation, 3 patients were unable to provide informed consent due to dementia or 
mental illness, 1 patient was blind and therefore unable to read the provided information, 
and 1 patient was non English speaking. The remaining 75 patients provided informed 
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consent, completed the pre-intervention FH-15 Survey and Incidence of Hypoglycemia 
(IoH) question and were provided with the educational tool for their perusal and 
application to self-management. It was later discovered in Phase Three of the project that 
Participant 10 had not answered all of the questions on the pre-intervention FH-15 
Survey and this was not immediately noted by the PI. Participant 10 was excluded to 
preserve the integrity of the project. The project population was recalculated to be 74 
participants. The continuation of the project saw an additional 14 participants lost 
through attrition. Participants 21 and 45 were withdrawn due to hospitalization and 
Participant 26 was withdrawn due to an inability to continue participation due the acute 
illness and hospitalization of a spouse. Participants 15, 27, 41, 51, 54, and 63 were 
withdrawn from the project due to lack of participation as evidenced by admitted failure 
to read the provided educational information. Participants 20, 23, 31, 48, and 74 were 
withdrawn from the project due to an inability for the PI or assistant LPN trained in the 
protection of human participants to make contact with the patient to administer the 
Post-intervention FH-15 Survey and IoH question within the required time frame. Sixty 
of the initially enrolled 74 participants included in the Pre-Intervention data were able to 
be queried with the Post-intervention FH-15 Survey and IoH question four weeks after 
the intervention. The project was noted to have an attrition rate of 19% and a response 
rate of 81%. The project population was finally recalculated to have an N=60. This was 
considered adequate for survey research by the APN project investigator.  
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Data Results and Analysis 
 Data was collected on a convenience sample and identified as the project 
population (Appendix K). A mixed method analysis of the project data was performed 
using both observational and statistical methods. Observational data was recorded to 
investigate the topic and expand on the statistical analysis. Statistical analysis was 
utilized to assist in the interpretation of the observational data and to assist in 
establishing whether the influence of the intervention was significant allowing for the 
rejection of the null hypothesis. The null hypothesis in the project was assumed to be 
that the intervention had no influence on FoH or IoH.  
 Project population demographics 
 Participant demographics were compiled for descriptive analysis (Appendix L). 
Participants ranged in age between 18 and 80+ years with the 60-69 year old age group 
having the highest number of participants at 38%. Thirty-one participants, 52% of the 
project population, were male and 29 participants, 48% of the project population, were 
female. One participant was African-American and 59 participants were Caucasian.  
Thirty-five participants, or 58% of the project population, were maintained on insulin 
mono-therapy during the project while 25 participants, or 42% of the project population, 
were maintained on a combination of insulin along with other oral or non-insulin 
injectable agents used to treat diabetes. Forty-nine participants, 82% of the project 
population, were noted to reside with another person(s) while 11 participants, 18% of the 
project population, resided alone. 
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 Descriptive Statistics. 
 The project data was descriptively expressed in order to summarize the 
characteristics of the project population.  
 Total project population. 
 The mean pre-intervention FH-15 score in the project population was 28 with 
FH-15 scores that ranged from 15 to 68. Thirty participants, representing 50% of the 
project population, were noted to have FoH pre-intervention as evidenced by FH-15 
scores of ≥28. Thirty participants, or 50% of the project population, did not have FoH 
pre-intervention as evidenced by FH-15 scores of <28. The mean post-intervention FH-15 
score in the project population was 25 with FH-15 scores that ranged from 15 to 65. Post-
intervention FoH scores were reduced in 37 participants, or 62% of the project 
population, unchanged in six participants, or 10% of the project population, and 
increased in seventeen participants, or 28% of the population. Post-intervention FoH 
was noted in 19 participants, or 32% of the project population.  
 The mean pre-intervention IoH in the project population was 4.7 with a range of 
IoH between 0 to 35 events within the four weeks preceding the intervention. The mean 
post-intervention IoH score in the project population was 4.3 with a range of 0 to 30 
events within the four weeks after the intervention.  Post-intervention, IoH was reduced 
in 25 participants, 42% of the project population, unchanged in 20 participants, or 33% 
of the project population, and increased in 15 participants, or 25% of the project 
population (Appendix M).   
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 FoH sub-populations. 
 The sub-population of participants with pre-intervention FoH was of particular 
interest to the PI. Post–intervention FH-15 scores in the 30 participants noted to have 
pre-intervention FoH demonstrated that 17 participants continued to demonstrate FoH 
post-intervention as evidenced by a FH-15 score ≥28.  Characteristics of the sub-
population are noted in Table 1.  
Table 1  
FoH Population Demographics 
 Age Gender Ethnicity Therapy Living 
Situation 
Pre-
Intervention  
 
Range: 
30-80+ 
years 
M=13 (43%) 
 
F=17 (57%) 
C= 29 (97%) 
 
AA= 1 (3%) 
I=23 (77%) 
 
I+=7 (23%) 
W/O=23 (77%) 
 
A=7 (23%) 
Post-
Intervention  
 
Range: 
30-79 
years 
M=6 (20%) 
 
F=11 (37%) 
C=16 (97%) 
 
AA=1 (3%) 
I=13 (43%) 
 
I+=4 (13%) 
W/O=14 (47%) 
 
A=3 (10%) 
 
M= Male F= Female C=Caucasian AA=African American 
 
I= Insulin Mono-therapy I+= Insulin with other agents W/O= With Another A= Alone 
  
Comparative analysis of the pre-intervention participants with FoH (n= 30) 
versus that of the post-intervention participants with FoH (n=17) demonstrated a 57% 
reduction in FoH within the sub-group. Trends in the post-intervention FoH as they 
correlate with the trends of post-intervention IoH in participants who demonstrated 
pre-intervention FoH are noted in Table 2. 
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Table 2 
Pre-intervention FoH population post-intervention trends 
 
 
IoH Increase IoH Decrease IoH without change 
FoH Increase (n=4) 
 
2 (7%) 1 (3%) 1 (3%) 
FoH Decrease (n=24) 
 
7 (23%) 12 (40%) 5 (17%) 
FoH without change            
(n=2) 
0 (0%) 1 (3%) 1 (3%) 
 
*Percentages were rounded to the nearest whole number for reporting purposes 
  
Alternatively, an additional sub-population was identified in the QI project. It is 
noteworthy that two participants, Participant 35 and Participant 61, did not 
demonstrate FoH pre-intervention; however, both participants demonstrated a higher 
post-intervention FoH score and both participant’s post-intervention scores were 
consistent with FoH. Interestingly, despite Participant 35 being male and Participant 61 
being female, the two participants shared the age group of 70-79 years, Caucasian 
ethnicity, insulin mono-therapy, and a living situation of residing with another. The 
development of FoH in these two participants demonstrates a 7% rise in FoH post-
intervention in a sub-population of participants that did not demonstrate pre-
intervention FoH.   
Statistical analysis. 
 Project outcomes were measured using the FH-15 Survey and patient self-
reported IoH pre and post intervention. The FH-15 Survey measured 15 participant 
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responses ranked according to experienced frequency of hypoglycemia and its impact on 
daily life pre-intervention and four weeks post-intervention. The IoH question collected 
each participant’s self-reported estimated incidence of the number of hypoglycemia 
events experienced within the four weeks prior to the intervention and four weeks post-
intervention. The pre- and post-intervention data for both FoH and IoH was statistically 
analyzed.  
A paired two-tailed t-test was performed to assess the differences between pre- 
and post-intervention FH-15 scores and IoH estimates from the 60 qualified participants 
which comprised the project population. Results were statistically significant (FoH-
M=26.5, SD=10.7, t (59) =3.47, [p = 0.001] with a CI of 95%) for FoH. This supported that 
the intervention did influence the FoH with statistical significance in this particular EBP 
and the null hypothesis could be considered for rejection. Results were not statistically 
significant (IoH- M=3.58, SD=6.1, t (59) =0.65, [p = 0.5]) with a CI of 95%) for IoH. This 
supported that the intervention did not influence IoH with statistical significance in this 
particular EBP and the null hypothesis could not be rejected. A summary of the 
statistical analysis data is noted in Table 3. 
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Table 3 
 Population Statistical Analysis Summary  
N   
Pre-
Intervention 
FH-15 Score 
Post-
Intervention 
FH-15 Score  
Pre-
Intervention 
IoH 
Post-Intervention 
IoH 
60 
Sample 
Mean 27.95 25.03 3.80 3.40 
  
Population 
Mean  26.49 3.58 
  Sample SD 11.032 10.314 6.208 6.087 
  
Population 
SD 10.734 6.126 
  SE  1.4243 1.3315 0.80141118 0.7858087 
  
 
p Value 0.000965827 0.518400569 
 
 Thematic Reports. 
Participant commentary was solicited by the PI or LPN assistant trained in the 
protection of human subjects at the conclusion of the post-intervention query by asking 
participants if they had any additional information they would like to offer regarding the 
information that was provided. Nineteen participants offered no additional comments. 
Forty-one patients had brief remarks suggesting the provided information was valuable 
in assisting with self-management. Six participants provided brief remarks suggesting 
the information increased self-management behaviors along with assisting in self-
management. Two themes arose surrounding participant’s perceptions of the 
intervention: education assisted in self-management and increased self-management 
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behaviors.  These thematic reports in the observational project were identified for 
potentially providing information that would stimulate future scholarly inquiry. These 
themes were reported during the collection of information while evaluating a different 
objective and could not infer any cause, effect, or change in practice. The themes did 
serve to observationally assist in the evaluation of the impact of the pedagogical tool.  
Relationship of Results to Framework 
 The EBP was guided by the ACE Star Model. The ACE Star Model focused on the 
transformation of evidence for use in clinical practice. The use of this framework assisted 
the PI in the translation of knowledge from bench to bedside. The results of the project 
demonstrated the effectiveness of the ACE Star Model as an approach to scholarly 
inquiry. Evidentiary information regarding the topic of inquiry, along with critical 
appraisal of best practice standards, were investigated, contextually translated, and 
practically applied using clinical expertise in a specified population. The results of the 
project, made possible through the guidance of the ACE Star Model, were relevant to 
improving patient safety and quality care, stimulating practice change, and generating 
additional scholarly inquiry.  
Relationship of Results to Objectives 
 The objective of the EBP was to add to nursing knowledge and translational 
diabetes research through the demonstration of the application of best practice 
strategies for improved quality of care and patient safety. This objective was realized 
through the completion of the project and dissemination of the data. The outcomes of the 
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EBP were an anticipated reduction in FoH as well as a reduction in IoH within the four 
weeks following the intervention as evidenced by comparative analysis of observational 
and statistical data collected during the project. The EBP utilized an observational 
approach to ascertaining whether education influences the FoH and the IoH in insulin 
requiring diabetics within a four week time frame. The PI made the initial assumption 
that the provision of self-management education derived from BGAT practically 
addressing the topic of hypoglycemia in insulin requiring diabetics would lead to a 
reduction in the FoH and IoH.  
Conclusion  
This project was devised in an attempt to validate that a relationship existed 
between the provision of diabetes self-management education and the fear and incidence 
of hypoglycemia. The extracted data that was analyzed for this project confirmed that a 
relationship existed between the project intervention and FoH, but no statistically 
significant relationship was evident between the intervention and IoH.      
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Chapter Seven: Implications 
Introduction  
 The incidence of diabetes continues to rise and along with the population of 
patients requiring insulin therapy. Insulin is a necessary form of therapy that is often life-
sustaining and remains a key to the prevention of diabetic complications associated with 
hyperglycemia. However, the use of insulin increases the risk of hypoglycemia and has 
been identified as one of the most common medications associated with ADEs. Insulin 
requiring diabetic patients are called upon to balance the threat of hyperglycemia with 
the risk of hypoglycemia on a daily basis. Insulin use frequently triggers a FoH as the risk 
of hypoglycemia is perceived by many patients to be an experience far worse than the 
any potential future threat posed by hyperglycemia. FoH serves as a major barrier in 
achieving the degree of glycemic control adequate enough to prevent complications from 
arising (Wild, 2007). Evidence has indicated that a multipronged approach to diabetes is 
needed and addressing self-management skills and the topic of hypoglycemia with 
patients is crucial (Seaquist, 2009). The purpose of the EBP was to add to the knowledge 
base of translational diabetes research and provide a demonstration as to how the 
application of best practice strategies can be translated into real world clinical practice 
in an effort to improve quality of care and patient safety. The EBP provided statistical 
and observational data supporting the fact that individualized education reduces FoH 
and IoH in insulin requiring adult diabetic patients.  
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The purpose of this chapter is to discuss the implications for nursing practice 
associated with the project, identify the strengths and limitations of the project, and 
detail how the project was guided by the eight Essentials of Doctoral Education for Advanced 
Nursing Practice developed by the American Association of Colleges of Nursing (AACN, 
2006). 
Implications for Nursing Practice 
 Insulin requiring diabetes mellitus is a chronic disease that continues to impose 
substantial risks to the health and well-being of individuals, families, communities, and 
the healthcare system at large. Nurses are obligated to use scientific evidence and 
nursing knowledge to provide healthcare with respect for human dignity regardless of a 
patient’s socioeconomic status, personal attributes, or nature of their health diagnosis 
(ANA, 2006). This EBP was demonstrative in showing that a chronic disease can be 
influenced by self-management education. It validated that the CRNP can engage in 
scholarly inquiry with success. A more in-depth discussion regarding the strengths, 
limitations, and linkage to the AACN (2006) Essentials of Doctoral Education for Advanced 
Nursing Practice reveals more specific implications of the EBP as it related to nursing 
practice.  
Strengths of the project. This EBP provided additional information that added 
to nursing knowledge and diabetes translational research for the purpose of improving 
quality care and patient safety. An analysis of the observational data generated by the 
project indicated that best practice standards involving education supporting self-
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management positively influenced FoH in insulin requiring diabetics despite the 
inability to determine an influence on IoH. The project was backed by an exhaustive 
literature review that summarized key evidence supporting the need and methodology of 
the project. Statistical analysis indicated that the ability to reject the null hypothesis 
allowed for the conclusion that the intervention was most likely responsible for the 
influence on FoH rather than sheer happenstance. This reaffirmed previous diabetes 
translational research demonstrating the importance of self-management education in 
diabetic patients. The EBP was an example of how the CRNP can identify a clinical need 
and translate scientific evidence from the bench to the bedside by developing an 
intervention to improve population health and promote patient safety in a cost effective 
manner.  The project clearly provided a basis for organizational change and stimulated 
the need for additional scholarly inquiry. The sample size was considered to be of an 
adequate nature considering a project of this type.   
  Limitations of the project. The results of the project must be interpreted with 
caution despite the generally positive results from the observational data and statistical 
analysis. This observational study used a convenience sample and could not infer 
causality. It was more valid than reliable as no control group was utilized. Other 
identified limitations included: conduction of the intervention by one HCP from one 
clinical discipline in one specialty setting, limited experience of the PI with translational 
research, and a short time frame used to demonstrate the effectiveness of the 
intervention. Thus, evaluation of long term effects, influence on glycemic control and 
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improvement of long term outcomes could not be performed. The levels of evidence used 
to support the intervention were not considered to be substantially high as there was a 
lack of clinical evidence on interventions addressing FoH and IoH that were noted to 
improve patient outcomes. The project demonstrated a lack of cultural diversity as the 
large majority of patients were located in one geographical area and were of Caucasian 
ethnicity. Some of the participants were long term patients of the PI with the prior 
establishment of a provider-patient relationship; an influence from an established 
relationship on the project could not be fully excluded. Recall bias was also considered a 
significant limitation to the project as survey information was based on patient’s 
perceptions of hypoglycemia and recollection of hypoglycemia without actual 
documentation. Albeit that this is how true to life clinical practice operates, it was 
required to be factored into the evaluation of the project for determination of project 
reliability. 
Linkage to DNP essentials. A practice oriented doctoral program is designed to 
provide nurses with the skill level needed to practice using innovation, evidence, and 
credible research findings. The DNP Essentials provided the framework for the doctoral 
program and addressed the foundational competencies that are core to the advanced 
practice nurse role. Incorporation of the DNP Essentials into the scholarly project assured 
its theoretical authenticity (AACN, 2006).  
 Essential I: scientific underpinning for practice. It was evident within the 
relevant literature that insulin induced hypoglycemia and the FoH required a 
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psychoeducational approach to aid patients in self-management for the prevention of 
diabetic complications. However, a practical approach that could be utilized in daily 
clinical practice eluded the PI and was identified as an area that required additional 
translational research. This project utilized the synthesis of knowledge from multiple 
disciplines, an evidence based approach using scientific information and theory, and the 
development of an intervention in the form of a patient-centered, pedagogical tool that 
assisted in the translation of research from bench to bedside. 
 Essential II: organization and systems leadership for quality improvement 
 and systems thinking. Diabetes care may be initiated with the forging of a 
relationship between the provider and the diabetic patient, however effects of this 
relationship extend far beyond a singular partnership to include families, communities, 
and healthcare systems. Chronic care management exhausts resources and places a high 
burden on society. This EBP was performed after assessing: the needs of the diabetic 
patient, the impact iatrogenic hypoglycemia has on families, the risk associated to the 
community, and the need for organizational changes for the improvement of population 
health. It focused on the development and evaluation of a practical, evidence based care 
approach for improvement in patient safety in a cost effective manner and served as an 
initial step in organizational change.  
 Essential III: clinical scholarship and analytical methods for evidence-based 
 practice. This project involved an exhaustive review of the relevant clinical 
literature, critical appraisal of the available evidence, the development of a clinical 
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question, and a needs assessment. It was deemed necessary to address FoH as it serves as 
a major barrier in the achievement of glycemic control and does not receive the attention 
that it clinically deserves. The project intervention was based on up to date clinical 
practice guidelines. Information technology and research methods were employed for the 
ethical collection of data, data organization, data analysis, and data interpretation. This 
project extracted relevant components of BGAT for translation into real life practice to 
influence the FoH and IoH. The results demonstrate that this EBP was also able to 
identify gaps in clinical research for additional query.  
 Essential IV: information systems/technology and patient care technology for 
 the improvement and transformation of health care. The use of technology to 
augment care management and innovation is essential. Doctoral prepared CRNPs are 
educated to gather information, determine appropriate use of technology, and determine 
the ethical application of available tools to delivery care (McGonigle and Garver-
Mastrian, 2015). This project used technology from its inception to conclusion. 
Technology was employed in the evaluation of relevant literature, the organization of 
data, the development of the pedagogical tool and the data analysis. The project was 
designed and planned using patient care technology, information technology, and 
available communication systems. Computer systems, computer software programs, 
electronic medical records, and telephone systems were all utilized ethically and in 
accordance with regulatory and legal guidelines.   
100 
 
 
 
  
 
 Essential V: health care policy for advocacy in health care. The prevention or 
early detection of complications associated with chronic disease is essential at an 
organizational and population level for the preservation of health and the conservation of 
valuable resources. This project demonstrated that the intervention influenced the FoH 
in a positive manner. This EBP is a beginning step in organizational change; but, 
although performed on an organizational level, its reach extends beyond the 
organization. Dissemination of the project information on an organizational level can 
stimulate changes across multiple facilities for improved quality of care and for improved 
health care outcomes in the diabetic population. The organizational policy change can 
assist in cost savings and the equitable distribution of valuable resources. Innovative 
interventions that reduce cost and risk while improving quality of life are valuable and 
cumulatively impact upon the health of our nation physically, financially, and socially.  
 Essential VI: interprofessional collaboration for improving patient and 
 population health outcomes. The complexity of health care delivery requires a 
team approach and the skill sets of multiple disciplines. Doctors of Nursing Practice 
(DNPs) are prepared to serve as effective leaders and facilitators of communication. A 
collaborative approach is required in chronic care management. DNPs are professionally 
prepared to act as conductors of health care delivery and to orchestrate the 
interdisciplinary management of care with the patient centered in the spotlight. DNPs 
are not required to be expert in every field; however, DNPs are expected to know how to 
get expert input for care management by tapping into the expertise and literature of 
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other disciplines. This project involved seeking commentary from medical, nursing, 
physician assistant, information technology, and non-clinical personnel. It also involved 
research from nursing, medicine, physical therapy, education, and psychology. The fusion 
of multidisciplinary input was utilized to conceptualize, design, implement, and evaluate 
the project despite the fundamental reliance on nursing knowledge.  
 Essential VII: clinical prevention and population health for improving the 
 nation’s health. Prevention is key to achieving the goal of improved health and 
well-being of our nation’s population. Using evidence based best practice standards, the 
DNP impacts upon the reduction of incidence, severity and development of 
complications associated with chronic disease. This project demonstrated how 
education can influence the FoH in insulin requiring diabetics. It also illuminated 
additional avenues for future scholarly inquiry to further the cause of diabetes 
management. Direct attention to the recognition, prevention, and appropriate 
management of hypoglycemia is encouraged in National Action Planning (HHS, 2014). 
This project demonstrated a move toward that national goal.   
Essential VIII: advanced nursing practice. 
The DNP can design, implement, and evaluate interventions while accounting for 
the differences in patients in a culturally sensitive manner (AANC, 2006). The DNP can 
skillfully identify issues in clinical practice that require scholarly inquiry for the 
improvement of individual and population health. The expertise attained from terminal 
level education in nursing advances the nursing practice into a whole new dimension. 
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This project was based on evidence and grounded in theory. Most importantly, this 
project was motivated by the principle of caring. Advanced practice nurses are 
particularly prepared to address the needs of the whole person, not just their disease, as 
the basis for advanced practice nursing is rooted in justice and compassion. Advanced 
practice nursing allows for the expression of love for fellow man and recognition of the 
frailty of the human condition. The desire to improve patient health through advanced 
practice nursing was the impetus for this EBP.  
Conclusion 
 The dynamic healthcare environment demands the application of high levels of 
evidence combined with practice expertise. Advanced practice nursing offers a distinct 
perspective to healthcare delivery that is unlike any other discipline. DNPs are equipped 
to design interventions based on scientific evidence using the art of nursing and clinical 
expertise to transform knowledge. This project: was influenced by concepts from 
multiple disciplines, transformed research using nursing knowledge into a more practical 
application that was utilized in daily practice, demonstrated a positive and statistically 
significant influence on patient care, and stimulated the need for additional research for 
the improvement of patient outcomes. Despite its limitations, it demonstrated devotion 
to quality improvement, use of a patient-centered approach based on scientific evidence, 
and a compassionate commitment to patient safety.  
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Chapter Eight: Project Conclusion 
Summary and Conclusions 
 Iatrogenic hypoglycemia is a serious ADE that is predominantly associated with 
insulin therapy. It serves a major obstacle for patients and providers in attaining the 
degree of glycemic control adequate enough to prevent diabetic complications from 
hyperglycemia. Hypoglycemia has physical, financial, safety, and psychosocial 
ramifications to individuals, families, communities, and healthcare systems.  The 
population of individuals with diabetes is expected to reach astronomical proportions in 
the coming years and it is anticipated that the population of patients requiring insulin 
therapy will continue to rise as well. Currently, up to 12% of patients with diabetes use 
insulin therapy translating into a population of over 4 million individuals nationwide 
(CDC, 2013). Diabetes is a chronic disease that is predominantly self-managed. Insulin is 
a life-preserving or life-sustaining form of therapy that cannot be avoided. There is a lack 
of clinical attention to the topic of hypoglycemia in the efforts to address hyperglycemia. 
It has been discovered that FoH is a frequently occurring problem for a large percentage 
of individuals on insulin therapy. FoH is notably a huge barrier in achieving glycemic 
goals as the tangible effects of hypoglycemia are often more distressing to patients than 
the future risk of complications from hyperglycemia (Wild, 2007). There is a definitive 
need to address the issue through autonomy supported education, patient 
empowerment, shared decision making, and individualization of goals to improve quality 
and patient safety. Reducing the impact of hypoglycemia has been identified as a 
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national priority by HHS (2014). However, there is less available evidence on how to 
accomplish this goal indicating gaps in research. The need to combat this complex 
problem served as the impetus for the EBP.  
The clinical question that arose was “does individualized self-management 
education influence the FoH and the IoH in adult patients diagnosed with insulin 
requiring diabetes mellitus within 4 weeks?” In order to answer this question, a 
thorough review of the relevant literature ensued. Multiple educational strategies were 
identified to address hypoglycemia. BGAT, a psychoeducational intervention, was 
discovered to be effective in reducing FoH in randomized clinical trials. However, 
implementing BGAT programs is less practical in real life and in healthcare systems with 
limited resources despite the noted benefits on improving care. Thus, information from 
BGAT regarding hypoglycemia was extracted and a pedagogical tool was developed from 
the extrapolated data for use in daily clinical practice in an attempt to translate research 
from the bench to the bedside to address FoH and IoH. The focus of the pedagogical tool 
was the recognition, prevention, and treatment of hypoglycemia. Preparation for project 
implementation included training on the protection of human subjects and University 
IRB approval to ensure the project met with ethical standards. It was determined that an 
observational study of a convenience sample would take place with retrospective data 
collection from the EMR. The ACE Star Model for knowledge transformation guided the 
process. The APN project manager applied best practice standards to all adult, insulin 
requiring diabetics over an allotted time frame in a single endocrinology practice setting. 
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Sixty participants were included in the project with 30 participants noted to have pre-
intervention FoH. FoH was measured pre- and four weeks post-intervention using the 
FH-15 Survey and IoH was measured through patients’ self-reports pre- and four weeks 
post- intervention. Statistical analysis of the project results indicated that the 
intervention did statistically influence FoH but failed to achieve statistical significance 
in influencing IoH in the specified population. A comparative analysis of descriptive data 
indicated a favorable impact from the intervention on FoH and IoH overall. 
Interprofessional collaboration and the use of informational technology was included 
from the inception of the project to its completion. The EBP was linked to the AACN’s 
DNP Essentials (2006). The implementation and the results of the project added to the 
nursing and translational research knowledge bases while being rooted in science and 
caring. This patient centered EBP takes quality of care and patient safety another step 
closer to meeting national goals.   
Dissemination Plans  
 The dissemination of research findings is an important method used to share 
information to improve quality care, improve population health, identify mistakes or 
pitfalls, influence policy change, reduce cost and close the gaps in research. The research 
finding associated with the project that is worthy of dissemination is individualized self-
management education does  influence the FoH in adult patients diagnosed with insulin 
requiring diabetes mellitus within 4 weeks.  The project results have the potential to be 
used in an interdisciplinary fashion to stimulate practice changes or for repetition to 
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demonstrate reliability. The primary end users of the information include HCPs, 
individuals with diabetes, or individuals associated with the provision of care to 
individuals with diabetes. Initially, the dissemination of data will be released during the 
oral defense of the DNP Capstone project to a small group of nursing peers for critique. It 
is the intention of the PI to summarize and distribute the results on an organizational 
level to the physician Board of Directors, the Director of Clinical Operations, and the 
Director of Information Technologies. It is hoped that the project will stimulate an 
organizational change in how data is collected in the EMR for future evaluation 
demonstrating quality of care initiatives and an improved ability to track population 
data. Additionally, it is the anticipation of the PI that Misericordia University will 
provide viewing of copyrighted Capstone projects for future reference by upcoming 
nursing students. The CRNP will continue to distribute information to patients and 
their family members in the PI’s individual practice setting. The possibility of posting the 
information on the organization’s patient teaching website will not be excluded from the 
realm of possibilities by the PI. The PI will communicate the results of the EBP to 
Professor Anarte-Ortiz at the University of Malaga in Spain to assist in the translation of 
the FH-15 Scale internationally. Widespread distribution of the results will only be 
considered after future collaboration with more experienced colleagues due to the 
limited expertise of the PI at this time. The adoption of information by patients, the 
organization, and collaborators for implementation into clinical practice or to stimulate 
additional translational research building on this project would be considered a 
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measurement of dissemination success. The PI will encourage feedback from end users to 
further improve quality of care. An additional measurement that will be used to monitor 
success of data dissemination for the project is the desire of other health care providers 
to engage in translational research or potentially participate in the development of a 
randomized controlled trial for improving input into clinical practice guidelines or 
participating in studies investigating the topic of interest. 
Future Ideas  
 It is the distinct intention of the PI to continue to pursue organizational change 
using the project results. National Action Planning (HHS, 2014) calls for improved data 
collection regarding the topic of hypoglycemia for prevention of ADEs and to further 
investigate the implications of the phenomenon. Incorporation of EMR prompts to 
improve recognition, prevention, and treatment of hypoglycemia will be sought. 
Consultation with IT personnel for data collection using identified prompts will be 
requested for further evaluation of the subject matter and to advance translational 
research.  
 The PI hopes that there is continued investigation regarding: the development 
and influence of FoH, the relationship between FoH and IoH and HbgA1C, the 
relationship between severity of hypoglycemia and FoH, the relationship between FoH 
and restoration of hypoglycemia awareness, how FoH is viewed and addressed among 
different HCPs who vary in discipline and health care settings, the effect of FoH on 
significant others, or the effect of a low FoH paired with high risk for hypoglycemia. 
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Conclusion  
 Translational research should not be conceived as applicable only to academia. It 
is the comingling of translational research with other knowledge sources such as 
research utilization, quality improvement initiatives, population data analysis, patient 
perspectives, and clinical expertise that makes the DNP an expert in translational 
science and evidence based practice (McGonigle & Garver-Mastrian, 2015).   Hence, the 
evolution of nursing knowledge and improvement of population health outcomes 
depends upon DNPs advancing the profession through clinical practice using the basic 
skills learned in academia.  
Nurses have a distinct viewpoint with which to see events and capture 
information in the clinical setting differently than any other professional discipline. The 
participation in translational research is the initial step that nurses need to take to 
demonstrate the insurmountable effect that the profession has on healthcare delivery. 
Translational research provides an avenue for DNPs to contribute to nursing knowledge 
and realize self-worth. This is a crucial step in in the process of solidifying the external 
perception of the professional identity of nurses as evidence based advanced 
practitioners. Nursing research is irrefutably influential in healthcare and its impact 
demonstrates that nursing independently holds itself to the highest professional 
standards thus fortifying its position as a profession worthy to share governance through 
accountability (Flaugher, 2009).  Nurses not only investigate the scientific and medical 
outcomes, but also take into consideration the broader determinants of health including 
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the humanistic and emotional outcomes of care. Additionally, nurses evaluate the 
importance of information noted by other members of the healthcare team (Brown, 
2010). Nursing plays a unique role in health care delivery. The evolution of healthcare 
requires the intellect, leadership, and compassion of nurses to build partnerships in the 
service of others.   
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Appendix A 
A Practical Guide to Recognizing, Preventing and 
Treating Hypoglycemia While Using Insulin
 
 
Introduction 
 The information that is contained within this booklet is meant to provide you 
some basic tips and strategies about how to recognize, prevent, and treat hypoglycemia. 
It is meant to help you manage your diabetes and keep you safe.  
 
 
 
Diabetes 
 Diabetes is a medical condition in which your body does not properly use food for 
energy. The food we eat is broken down, changed to sugar, and released into the blood. 
You have the power to control your 
diabetes- it does not have to control 
you! 
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The pancreas, an organ in the body that is located near the stomach, makes a hormone 
called insulin. Insulin is responsible for taking the sugar from the blood and carrying it to 
the cells of the body where it is turned into energy, or fuel. A person with diabetes either 
does not make enough insulin or cannot use insulin the way it should causing sugar to 
build up in the blood.  Abnormally high levels of sugar in the blood can lead to some very 
serious health related problems. These problems are typically referred to a diabetic 
complications. They include: blindness, kidney failure, painful nerve endings to the feet 
and hands, amputations of limbs, heart disease, liver disease, and could mean premature 
death.  
Insulin and Diabetes 
Healthy eating, routine physical activity, and taking medications by mouth can 
help to control diabetes. However, when a person with diabetes cannot 
maintain a blood sugar adequate enough to prevent diabetic 
complications, insulin therapy becomes a necessity. The need for insulin 
does not mean that a person with diabetes has “end stage diabetes” or 
“failed as a diabetic”. The need for insulin does not mean it is your fault. 
The amount of insulin that a person with diabetes needs is influenced by lifestyle habits, 
like dietary intake and exercise, but the need for insulin means that your pancreas does 
not work the way that it should. It is sometimes possible for a person with diabetes to 
stop using insulin by changing their lifestyle; but remember, it depends on your 
pancreas’s ability to make insulin. It is the degree to which you keep your sugar 
controlled that determines your risk of developing complications, not the type of 
medication that you use to control it!  
 
Hypoglycemia 
 You can ask almost any person with diabetes what one of their biggest concerns 
is with using insulin to control their disease and they will tell you that they worry about 
having a low blood sugar. A low blood sugar is called hypoglycemia. This occurs when 
the sugar in the blood drops below a normal level. Sugar is an important source of energy 
for the body. A low sugar is like a car that is running out of fuel. Hypoglycemia is a 
medical emergency and requires immediate attention. There is no need to panic, but 
treatment cannot wait! 
 Eating more food than the body can use at any given time causes the body to store 
extra sugar in the liver, the muscles, and in the fat where it can be used for energy in 
between meals. These stores of sugar can be used by the body initially when a low sugar 
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occurs. Unfortunately, however, when you are treated with insulin or other medications, 
it makes it much harder for the body to correct a low sugar as quickly.  
It is not wrong that you are concerned about a low sugar because this is a 
potential risk of insulin use; but you have to come to terms that you cannot prevent a low 
sugar by keeping your sugar elevated either. It’s all about balance!  
 
 
         Hypoglycemia       Hyperglycemia 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
What can a low sugar do to me? 
 Weight gain 
 Longer hospital stays 
 Increased medical costs 
 Reduction in quality of life 
 Fear 
 Depression 
 Anxiety 
 Struggle with personal relationships 
 Fear of dependency 
 Loss of control 
 Reduction in work productivity 
 Irregular heartbeat 
 Seizures 
 Inability to drive or operate machinery safely 
 Coma  
 Death 
 Hypoglycemia unawareness (the absence of warning 
symptoms of a low sugar due to repeated exposures) 
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A blood sugar is usually considered to be too low if it is below 70 mg. /dl, however, not 
all people with diabetes feel the same with a low sugar. Some people with diabetes do 
not have any symptoms when their sugar is low while others may feel like their sugar is 
low when it is not. Therefore, a sugar may be considered too low for some when it is 
below 70 or when it is low enough to cause symptoms that represent a threat to safety in 
others. It is important that you communicate with your health care provider the range of 
sugars that you can physically tolerate so that they are aware of your experiences. This 
allows both you and your provider to come to a joint decision on a target range for your 
sugar that is individualized to you. This is important to protect you from diabetic 
complications as well as to protect you from low sugars. Knowing your personalized 
target sugar range will allow you to better track your progress. 
My Glucose Target Range 
  
Self-Blood Glucose Monitoring 
 Monitoring your glucose is a vital tool used by both you and your 
health care provider in managing your diabetes. Generally, glucose 
testing is done before you eat a meal and/or at bedtime. However, you 
should always test your sugar with any changes in your symptoms, 
 
Before meal:                ________________________ 
2 Hours after Meal: ________________________ 
Bedtime:                     _________________________ 
The risk of having a low sugar does 
not have to be something that your 
fear 
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when starting new medication, with illness, or when changing your routine. This may 
involve you to test your sugar at varied times which may include 2 hours after eating or 
in the middle of your sleep cycle.  
The importance of testing your sugar is simply to help you make better decisions. 
Monitoring your sugar: 
 Tells you how you are responding to your individualized treatment plan 
 Shows you what things in your routine influence your sugar 
 Helps you adjust your treatment 
 Helps you to predict high or low sugars 
 Provides a useful tool to help you prevent diabetic complications 
 Gives you the evidence you need to match your symptoms to your sugar 
Keep in Mind 
Your readings can be false if: you are using the wrong strip, you are using the wrong 
technique, the meter is dirty, the meter is very hot or cold, your hands are dirty or wet, or 
there is not enough blood on the strip. 
Key Points:  
 It is very easy to become frustrated with testing your sugar especially if the 
results are not the ones that you want to see. It is very common to sometimes feel 
like you are trying very hard, but your sugars do not fall within your target range.  
Remember, your sugar reading is a reflection of how well your pancreas and 
your treatment plan are working. It is not a reflection of you as a person or 
the effort you are putting into your diabetes!  
 The information that you get from testing your sugar is very valuable because it is 
a way of giving you feedback. Feedback helps you to understand cause and effect. 
Using a sugar diary will help put the pieces of the puzzle together so you to make 
future improvements. The result of testing may not be what you wanted, but try 
not to get frustrated, angry, or defeated. Testing your sugar will keep you safe 
from harm, reinforce that you made the correct choice, or guide you to try a 
different way of handling a situation. Using your test results can show you areas 
that need improvement. The only results that will not help you are the 
ones you do not take! 
 Invest your time in keeping a written log of your blood glucoses to help 
identify patterns. A repeated pattern of abnormal sugars that occur on a 
daily basis at the same time will alert you to the need to have your daily 
treatment adjusted. Sometimes there is no daily pattern when you look at your 
glucose log. However, labeling abnormal sugar readings in your log book with a 
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one word phrase will help you to remember what caused the abnormal sugar. You 
will start to see certain events (cause) trigger an abnormal sugar (effect) even 
though these events may not be happening on a daily basis. Identifying these 
patterns can allow you to discuss them with your health care provider to alter the 
treatment plan and will help you to predict future abnormal sugars. For example,  
         
Breakfast Lunch Supper  Bed 
114 Walk 68 Pizza 214 155 
98 112 Walk 71 129 
124 Walk 64 147 Pizza 231 
Walking= low sugar   Pizza = high sugar  
Recognizing Hypoglycemia  
 You need to know the symptoms of hypoglycemia, or low sugars, so that you will 
not miss them if they happen. The longer you have diabetes, the easier it is to miss 
some of the symptoms of hypoglycemia. You are not to blame for that- here are some 
tips to help.  
 
 
 
 
Here is a list of the most common symptoms that occur in people who are having a 
low sugars.  
 
 
 
 
 
 
 
How Aware Are You? 
Keep in mind that the symptoms of a low sugar are not 
always related to a low sugar and the symptoms could be 
caused by other things; but if they are happening, it is 
important to test your sugar when possible to make sure you 
are correct. 
Tremors/shaking  Argumentative Nightmares 
Sweating   Poor Coordination Crying in sleep 
Blurred Vision   Poor Concentration Seizures 
Dizziness   Anger/Irritable Poor sleep 
Weakness   Slurred speech Damp pajamas 
Fatigue   Fast Heartbeat AM Confusion 
Headache   Confusion  Unconsciousness 
Hunger   Hunger  Slow reactions 
Nausea/upset stomach Anxiety   Numbness 
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Practice this exercise to help you become more aware of your symptoms. 
Keep a daily log of your symptoms. When you believe your sugar may be starting to 
get too low, do a quick head to toe self-assessment of how you feel. Start with your 
head and end with your toes. Jot your symptoms down on your log in the appropriate 
column. Next, based on how you feel, guess where your sugar is at the time and write 
it down in the estimated column then test your sugar and write the blood sugar 
result in the actual column.  
Sample Diary 
Date Time Symptoms Est. Actual 
6/1/15 5p Headache, Nervous 49 41 
  (this show you how to 
log the information) 
  
 
Now, let’s take a look at what you can do with the information you have collected: 
1. Find every single actual low sugar in the log 
2. List each individual symptom  
3. List the blood sugar value that occurred with each symptom 
4. Find the average by adding up all of the individual blood sugars that accompanied 
that particular symptom and then divide the total by the number of glucose 
readings.  
Example after collecting information for a week. 
Symptom  Average Blood Sugar 
Headache               53+66+64+61+49=293 / 5= 58 
In this example, headache occurred 5 times that was associated with a low sugar.  
The average blood sugar associated with headache is 58.  
Now:  
5. List the number of times you felt that symptom when you were low under 
frequency 
6. Find out how consistent the symptom is by dividing the frequency of the low 
blood sugar by the total number of low blood sugar entries on your log. This will 
help you to see which of your symptoms are the most reliable in helping you to 
recognize a low sugar.  
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Symptom/ Average Sugar/ Frequency/ Consistency 
Headache 58  5 x     5/10= 50% 
(This means that my log showed 10 low sugars in total with headache listed as a 
symptom 5 times out of 10; this means a headache happens 50% of the time 
when I am low) 
Pause: Take a deep breath and look at the example below. Be patient- it will 
not take long to figure this out and soon enough you will be a pro! Learning 
to link symptoms to hypoglycemia can allow you to intervene earlier and 
respond to subtle clues before hypoglycemia becomes disabling.  
Think Hypoglycemia! 
A person experiencing hypoglycemia, or low blood sugar, commonly has difficulty in 
performing routine daily tasks. See if these clues will help you to identify a low sugar 
before it is too late. 
Mental Clues 
Are you having trouble? 
Following directions 
Making change with coins or converting money 
Following a conversation 
Thinking of a correct word 
Reading 
Concentrating  
Doing simple arithmetic (count backwards from 100 by 3s) 
 
Physical Clues 
Are you having more difficulty-? 
Walking quickly and turning? 
Climbing stairs? 
Standing up? 
Bending over at the waist? 
Dancing? 
 
 
 
 
 
“I can’t write a check!” “I can’t hammer a nail!” 
“I can’t tie my shoelace!” “I can’t flip a dime!”  
Can you think of words that begin with a certain letter of the 
alphabet? 
Can you say “Peter Piper Picked a Peck of Pickled Peppers”? 
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Keep your eyes open for subtle clues to a low sugar. 
Am I having a hard time doing this simple task? 
Am I doing this task more slowly than usual? 
Am I making repeated mistakes? 
If this is the case, you should test your sugar! 
Listen to your body trying to warn you!  
When feelings and emotions are stronger or weaker than usual or when family or 
friends tell you that you are acting or looking different-TEST. 
 
 
Plot your actual sugar in one color on the left side of the grid and your 
estimated sugar in another color on bottom of the grid and connect the 
point where they intersect on the error grid 
 
 
Sugars that are plotted in the C, D, or E ranges show a need to talk to your 
provider  
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Preventing Hypoglycemia 
Risk Factors that trigger lows and how to deal with them 
Visual problems 
Know your limitations. If you have trouble seeing the dose on your insulin syringe, you 
need to bring this up to your provider. You may need a magnifier for your syringe, an 
insulin pen device, or prefilled syringes.  
Memory Problems  
You made need to ask for help from your provider, your family, or friends. Try an alarm 
on a clock or watch. Keep a written log of when you took your insulin. Try to keep a 
strict routine. Carry your supplies with you everywhere you go.  
If you cannot remember if you already administered your insulin dose, it is advisable that 
you do not administer insulin so you do not take the insulin dose twice. Instead, you 
need to notify your provider and test your sugar more frequently over the next 4-24 
hours. If you are noticing your sugar rapidly climbing, get instructions from your 
provider.  
Taking Insulin at the Wrong Time 
Taking insulin too early or too late is a common pitfall that causes low sugars. Do not 
fool yourself into thinking that just because you did this before you can repeatedly take a 
chance! Intermediate or long acting insulin does not need to be administered with a 
meal- but a rapid or short acting insulin meal dose must be timed around food. This 
ensures that your insulin will peak at the same time as your food reaches your system. If 
you are delaying a meal, you may need to have a small snack to prevent a low sugar and 
you should not take your short acting insulin until you eat. Carry your supplies- no 
shortcuts! 
Taking the wrong insulin  
This can happen to the best educated diabetics- do not panic. Immediately test your 
sugar so you know where you are starting from. If you took intermediate or long acting 
Am I forgetting 
what I am 
doing? 
Do my feelings 
match the 
current 
situation? 
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insulin by mistake, you will need to test your sugar every 1-2 hours for the duration of the 
action of the insulin. If you took rapid or short acting insulin by mistake, eat a snack and 
test your sugar hourly for the duration of the insulin action and have another snack if the 
hourly sugar drops below 100. Wait to take any additional insulin until you are sure the 
incorrect insulin is beyond its duration of action time. Alert a loved one or friend to 
check on you and call your health care provider for more instruction if needed.  
Prevention is best- label your insulin clearly- make yourself a checklist- use different 
appearing devices for different insulin to tell them apart.  
 
Scar Tissue (known as Lipohypertrophy) 
The longer you have used insulin, the more likely it is that you have injected into the 
same general areas to administer your insulin. This can cause scar tissue underneath the 
skin that does not absorb insulin the right way. If you start using fresh injection sites, 
you might notice you have low sugars because the insulin is absorbing better. Try to 
make sure you do not inject into a muscle as this can trigger low sugars. Prevention is 
best-regularly rotate your injection sites and if you start using new injection sites, 
monitor more closely.   
 
 
 
 
 
 
 
 
 
If there is any question in your mind that you are not using the right technique to 
monitor your sugar or take your insulin, please bring it up to your provider! 
Reduction or miscalculation of food intake 
This is a common trigger for low sugars. If you are starting a new diet, you may require 
changes in your insulin doses. Consider learning to carbohydrate count if you do not 
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already do so; it is important to know how carbohydrates and how the combination of 
carbohydrates with fats and proteins in your diet impact upon your sugar. 
Carbohydrates cause your sugar to rise rapidly and the effects do not last more than a 
couple hours; but when you combine carbohydrates with fats or proteins, your sugar 
may initially not spike up as high, but it may remain elevated for a longer period of time.  
 If you are sick to your stomach and feel like you may not be able to keep the food you are 
eating down without vomiting or you might not eat the amount of food that is customary 
for your typical insulin doses because of illness, dental problems, or scheduled tests for 
which you have to fast, you may need to consider waiting until immediately after the 
meal to take any short acting insulin to confirm you were able to consume the food; 
otherwise, your short acting mealtime insulin dose should be held. . You do not want 
your insulin peaking if you could not eat enough or vomit what you have just eaten. You 
should discuss a sick day plan with your health care provider as to how to adjust your 
insulin if this occurs. 
Activity 
Increased physical activity is also a common trigger for causing low sugars. The timing 
and type of your last meal, the timing and amount of your last insulin dose, you’re blood 
sugar before exercise, and the intensity of the physical activity all play a role in 
determining your risk. The important thing is to be prepared, test before, during and 
after, and realize that sometimes activity can lower your sugar several hours after you 
have completed the exercise depending on how long or how vigorously you exercised. 
More prolonged activity is more likely to progressively lower your sugar than short 
bursts of activity, but this can be unpredictable and may be difficult to figure out. 
You need to test your sugar before engaging in exercise because if you are below 100 or 
over 250, it is recommended that you delay your exercise. The optimal range for your 
sugar pre-exercise is 120-180. If you are too low prior to exercise, options include eating a 
carbohydrate containing snack for short duration activity or a combination of 
carbohydrate and protein for anticipated longer duration of activity. If you are scheduled 
to take short acting insulin within 2 hours of exercising, you may need to reduce the dose 
by 20-50% instead of consuming a larger quantity of food.  
Alcohol  
Alcohol use causes you to be more sensitive to insulin and it stops the liver’s 
ability to release stored sugar into the bloodstream for up to 12-14 hours after you 
drink. Initially, you might say that drinking alcohol raises your sugar. This may be 
true for a brief period of time due to the amount of carbohydrates (sugars) that the drink 
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contains. However, the effects of carbohydrates only last for a 1-4 hours, but the impact 
of the alcohol contained within the drink lasts well after the effect of the carbohydrates. 
The American Diabetes Association recommends no more than 1-2 drinks in a 24 hour 
time period for an adult female and no more than 2-3 drinks in a 24 hour period for an 
adult male. It is also recommended that you eat food when you ingest alcohol, test your 
sugar periodically while drinking and have a small snack before you go to bed. You may 
need to consider a reduction in your long acting insulin if you have been drinking. 
Consider setting an alarm during sleep if needed to test your sugar to make sure it is not 
low and alerting someone you live with (if possible) to test your sugar in the middle of 
sleep. Try not to drink alcohol when you have been more active than usual or are eating 
less than usual.  You must also be careful when drinking alcohol because it may mask the 
symptoms of a low sugar and you may not be able to tell if your sugar is low or it is the 
alcohol’s effect you are feeling.    
Delayed gastric emptying (Gastroparesis) 
Years of having diabetes can sometimes result in a condition called gastroparesis. This 
condition slows the emptying of food from the stomach. When food leaves the stomach 
slower than the rate of speed that your insulin starts to peak, it can predispose you to 
low sugars. If you have this documented condition, you may want to talk to your health 
care provider about taking any short acting insulin immediately after eating rather than 
before to better match how food is being absorbed into the system more slowly. 
Kidney or Liver Disease 
The effects of insulin can last longer in people who also have kidney or liver disease. The 
kidneys and liver are responsible for clearing insulin out of your system; however, people 
with kidney or liver kidney disease have less of an ability to remove insulin from the 
system as quickly and the action of the insulin can last longer thus increasing the risk for 
a low sugar.  
Weight Loss 
Weight loss, whether intentional or unintentional, can increase your sensitivity to 
insulin and make you more prone to low sugars. If your weight has been dropping, this 
can trigger a need to reduce your intake of insulin.   
Aging 
The aging process can sometimes make you more likely to have a low sugar. An aging 
nervous system does not have the same ability to alert you with symptoms of low sugars 
like it did when you were younger. Aging also affects your muscle mass and the way 
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insulin and food are absorbed in the body. The goal is to keep you healthy so you 
continue to age, but aging can increase the risk of having a low sugar.  
Other Medications or Supplements 
The risk of having a low sugar is higher when you take other diabetes medications in 
combination with insulin. Additionally, some complementary or alternative therapies 
including over the counter medications can make you more prone to low sugars. These 
include: Cinnamon, Fenugreek, Bitter melon, Ginseng, Nopal, Aloe Vera, Banaba, Caiapo, 
Bilberry, or Milk Thistle. You also need to be aware that use of any prescription or over 
the counter products that can cause sedation or slow your heart rate may have the ability 
to mask symptoms of low sugars.  
 
 
 
Be Prepared! 
Having a quick fix treatment available to treat a low sugar is extremely important. Make 
up small packets or treatment bags with non-perishable items containing carbohydrates 
and strategically place them in an area that you can access them at all times but do not 
use them or allow anyone else to use them unless you are having a low sugar. Some 
examples include: in your car, on different floors in your home, in your desk or locker at 
work, or on a keychain that you carry.  
Use a medic alert bracelet or necklace, shoelace tag, wallet identification card, or medical 
tattoo. Consider putting very pertinent data on your emergency screen of your cell phone 
if this is possible or consider an app for a smartphone that stores pertinent emergency 
data.  
Ask your provider to give you a prescription for a glucagon emergency kit and makes 
sure that you and your loved ones know how to use it.  
Alert people in close proximity to you if it is appropriate in the event of an emergency. 
Keep your loved ones informed of where you are traveling.  
Driving, operating machinery, or completing tasks that require strict attention should 
not be attempted if you believe you could be experiencing a low sugar. You should 
immediately stop what you are doing, alert someone if possible, and eat or drink a form 
of sugar to correct the problem. If you are prone to unpredictable low sugars, you should 
By failing to prepare, you are preparing to fail- 
Benjamin Franklin 
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test your sugar before driving and for every 30 minutes of continuous driving to ensure 
your safety and the safety of the public. Severe hypoglycemia can cause you to lose your 
driving privileges or cause serious injury if you are attempting to operate machinery.  
 
 
The Action of Insulin  
Insulin is a medication that lowers your blood sugar and substitutes for the inability of 
your pancreas to make enough insulin. There are many types of insulin and each act 
differently in the body. It is important for you to know how your insulin works. The 
onset of the insulin’s action refers to when the insulin starts to work. The peak of the 
insulin’s action refers to when the insulin is at its greatest potential for lowering your 
sugar. You are most likely to have a low sugar when your insulin is at its peak action, 
especially when physical activity or reduction in food intake occurs at the same time. 
The duration of insulin’s action refers to how long the insulin works in your body.  
The following chart with help you to understand how your insulin works. 
Type of Action Name When to 
Take 
Onset Peak Duration 
Rapid Acting 
(also referred to as bolus 
or mealtime insulin 
Humalog 
Novolog 
Apidra 
Afrezza 
 
0-15 
minutes 
before the 
meal  
10-30 
minutes 
30 
minutes 
to 3 
hours 
3-5 hours 
Short Acting (may also 
be referred to as bolus 
or mealtime insulin) 
 
 
Regular 
(R)  
15-30 
minutes 
before the 
meal 
30-60 
minutes 
2-5 
hours 
Up to 12 
hours 
Intermediate Acting NPH (N) Does not 
need to be 
given with 
a meal 
90 
minutes 
to 4 
hours 
4-12 
hours 
Up to 12 
to 24 
hours 
Long Acting (also 
referred to as basal or 
background insulin 
Lantus 
Levemir 
Toujeo 
Does not 
need to be 
given with 
a meal  
45 
minutes 
to 4 
hours 
Very 
little 
peak 
Up to 24 
hours 
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Practice plotting the time you take your insulin and calculating when your insulin 
will peak to help you anticipate where you may be at most risk to have a low sugar.  
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Users of Humalog, Novolog, Apidra, Afrezza or Regular ® 
You may have been advised to take these insulins when you eat (mealtime insulin dose) 
or to add additional insulin units (correction insulin dose) to your usual doses if your 
sugar before a meal is elevated.  
Mealtime insulin doses should be held if your sugar is too low until it has been corrected 
and retested. It should also be held in the event you are not eating a meal.  
 If you take doses of insulin too close together, the ending action of the previous insulin 
injection can overlap with the beginning action of the next insulin injection and can 
“stack” the effects of the insulin action on top of one another. This is known to 
predispose you to a low sugar when the two different insulin doses are working at the 
same time and is known as “stacking insulin”. You may need to consider a reduction in 
any short acting insulin doses that follow a previous short acting insulin injection within 
1-3 hours. 
Users of Lantus, Levemir, Tujeo or NPH 
You may have been advised to take these insulins one or two times daily, but they are not 
required to be administered with food. You should avoid prolonged meal skipping. If 
your sugar is too low at the time you are due to take the dose, correct the sugar to an 
acceptable range before administering the dose. This insulin should be kept on a routine 
schedule.  
 
Treatment of hypoglycemia 
Treating low sugars can sometimes feel like you are on a rollercoaster ride. There are a 
few simple tips that you need to adhere to when treating low sugars so your body can 
adapt.  
If it is not possible to verify your sugar by testing, for safety sake, you should treat 
immediately anyway. However, it is better to be prepared and carry your meter so you 
can verify the symptoms you feel are actually a low sugar.  
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Remember the Rule of 15 
Treat a low sugar with 15 grams of carbohydrate; wait 15 minutes; retest sugar and repeat 
if still low; once corrected, repeat glucose one hour after to confirm not recurrent. 
Example items to treat a low sugar can include: 3-4 glucose tablets, ½ can of regular 
soda, 4 ounces of fruit juice, 2 tablespoons of raisins, 1 tablespoon of sugar, or 8 ounces of 
non-fat milk 
Glucagon should be given if you are unresponsive.  
Keep in mind that once you eat or drink something it will take a minimum of 10-15 
minutes for your symptoms to stop and another 15 minutes before you feel better. If you 
continuously keep eating until your symptoms are gone, this will result in overtreatment, 
a high blood sugar, and can lead to weight gain. 
If you are going to eat a meal within 2-3 hours of having a low sugar, immediate 
treatment and continued surveillance is enough, but if you are not planning on eating a 
meal within the next 2-3 hours after having the low sugar, you should follow up the 
initial treatment with a protein food source. 
Try not to treat your sugar with an item that you love to eat as this sometimes leads to 
over-treating.  
It is VERY hard use your logic rather than letting your fear of  low sugar and the desire 
for the symptoms of a low sugar to go away as quickly as possible drive your choices; but 
you need to try to not to panic and follow a step by step approach to treating the low 
sugar. Do not over-react and do stick to one method to treat the low sugar.  
Once you have treated your low sugar, try to see if you can identify the trigger that could 
have caused the low sugar so you may react to the situation differently in the future.  
If you are taking Acarbose (Precose) or Glyset (Miglitol) in addition to insulin and you 
experience a low sugar, you must treat with dextrose only as the these medications may 
slow the rate of absorption of other types of carbohydrates. 
General Rules of Thumb  
Always bring a written list of ALL of your current prescribed and over the counter 
medications to EVERY visit with your health care provider.  This may seem very 
annoying, especially when things do not change much, but this is a very critical 
part of communication that is needed as health care providers often rely on your 
reports of what medication you are or are not taking.  
Check expiration dates of insulin, test strips, glucagon, or other supplies. 
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Let your provider know if you need new equipment. 
Know your glucose targets.  
Bring a glucose log with at least 3-5 days of recorded glucoses to your healthcare visits.  
Involve your friends and family in education and treatment. They want to help and need 
to know how. 
Protect yourself and others around you by using your common sense and testing your 
sugars.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Knowledge + Action = Power 
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Appendix B 
FH-15 Scale 
1. How often do you fear not recognizing the symptoms of hypoglycemia? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
2. How often are you afraid of not knowing what to do in the event of 
hypoglycemia? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
3. How often are you afraid of having hypoglycemia at work? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
4. How often are you afraid of having hypoglycemia outside of a hospital or health 
care setting? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
5. How often are you afraid of hypoglycemia while alone? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
6. How often do you avoid social situations (meetings, outings, etc.) due to fear of 
having a hypoglycemic episode? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
7. How often do you stop doing things you used to for fear of having a hypoglycemic 
episode? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
139 
 
 
 
  
 
8. How often do you have hypoglycemia that makes you unable to drive or use 
machinery?  
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
9. How often do you have hypoglycemia that makes you unable to work?  
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
10. How often do you have hypoglycemia that interferes with your leisure activities? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
11. How often do you have hypoglycemia that interferes with your family life? □ 
Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
12. How often do you have hypoglycemia that interferes with your social life? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
13. How often do you worry about losing consciousness due to hypoglycemia? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
14. How often are you afraid of falling asleep for fear of having hypoglycemia at 
night? 
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
15. How often are you afraid of taking a trip/holiday for fear of experiencing 
hypoglycemia?  
□ Never     □ Almost Never     □ Sometimes     □ Almost Always     □ Every Day 
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Appendix C 
Measurement of Self-Reported Incidence of Hypoglycemia 
1. Estimate the number of times you have experienced hypoglycemia in the past 
four weeks. ___________ (Pre-intervention) 
2. Estimate the number of times you have experienced hypoglycemia in the past 
four weeks. ___________ (Post-intervention) 
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Appendix D 
 
Assumptions of the ACE Star Model of Knowledge Transformation for EBP 
 
1. Knowledge transformation is necessary before it can be used in clinical 
decision making.  
2. Knowledge is obtained from multiple sources.  
3. Generalizable knowledge is discovered through the research process.  
4. Evidence is hierarchically categorized according to the strength of the 
evidence as determined by rigor.  
5. Knowledge is found in different forms.  
6. Knowledge is relative to its contextual use.  
7. The form of the knowledge determines its utility.  
8. Knowledge is transformed by the steps of summarization, translation, 
integration, and evaluation  
(Stevens, 2004).  
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Appendix E 
The ACE Star Model 
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Appendix F 
Informed Consent 
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Appendix G 
Certification of Completion of Protection of Human Subjects 
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Appendix H 
Letter of IRB Approval 
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Appendix I 
LPN Assistant to Project Investigator Certification of Completion 
Protecting Human Subject Research Participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
The     H) Office   
    successfull     
      
 
   06/24/2015 
  1788732 
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Appendix J 
Project Implementation Timeline 
 
 
 
Phase 1
•6/2/15-6/12/15
•Acquisition of Informed Consent from Participants
•Completion of Pre-Intervention FH-15 Survey and Patient estimated 
Incidence of Hypoglycemia 
•Provision of Educational Tool and Instruction 
Phase 2
•6/13/15-6/29/15
•Education of LPN assisstant in Protection of Human Participants in 
Research
•Availability of Project investigator for questions and patient support
Phase 3
•6/30/15-7/17/15
•Administration of Post-Intervention FH-15 Survey and Patient 
reported Incidence of Hypoglycemia
Phase 4
•7/18/15-8/14/15
•Synthesis and Analysis of project data
•Dissemination of project data  
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Appendix K 
Data Table 
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Appendix L 
Population Demographics 
 
 
2 3
10
11
23
10
1
Participant Age
18-29 30-39 40-49 50-59
60-69 70-79 80+
59
1
Participant Ethnicity
Caucasian African-American
3129
Gender
Male Female
35
25
Therapy
Insulin Monotherapy
Insulin with other Agents
11
49
Living Situation
Resides Alone Resides with another
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Appendix M 
Population Descriptive Statistics 
  
 
 
  
 
 
 
 
 
3030
Pre-Intervention FoH
with without
19
41
Post Intervention FoH
with without
17
37
6
Post Intervention FoH 
Trend
Increase Decrease No Change
15
25
20
Post Intervention IoH Trend
Post Intervention IoH Trend Increase
Post Intervention IoH Trend Decrease
Post Intervention IoH Trend No Change
Pre
M = 4.7
Post
M = 4.3
